EP0960214A1 - DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER - Google Patents

DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER

Info

Publication number
EP0960214A1
EP0960214A1 EP97951529A EP97951529A EP0960214A1 EP 0960214 A1 EP0960214 A1 EP 0960214A1 EP 97951529 A EP97951529 A EP 97951529A EP 97951529 A EP97951529 A EP 97951529A EP 0960214 A1 EP0960214 A1 EP 0960214A1
Authority
EP
European Patent Office
Prior art keywords
seq
marker
pcr
prostate
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97951529A
Other languages
German (de)
English (en)
Other versions
EP0960214A4 (fr
Inventor
David Ralph
Gang An
Mark O'hara
Robert Veltri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Urocor Inc
Original Assignee
Urocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urocor Inc filed Critical Urocor Inc
Publication of EP0960214A1 publication Critical patent/EP0960214A1/fr
Publication of EP0960214A4 publication Critical patent/EP0960214A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates generally to the detection and diagnosis of human disease states and methods relating thereto. More particularly, the present invention concerns probes and methods useful in diagnosing, identifying and monitoring the progression of disease states through measurements of gene products.
  • the genetic detection of cancer has a long history.
  • One of the earliest genetic lesions shown to predispose to cancer was transforming point mutations in the ras oncogenes (Taparowsky et al, 1982).
  • Transforming ras point mutations may be detected in the stool of individuals with benign and malignant colorectal tumors (Sidransky et al, 1992). However, only 50% of such tumors contained a ras mutation (Sidransky et al, 1992).
  • Carcinoma of the prostate is the second-most frequent cause of male cancer-related death in the United States (Boring, 1993). The incidence of prostate cancer increased by 50% between 1980 and 1990 (Stone et al, 1994). Although relatively few prostate tumors progress to clinical significance during the lifetime of the patient, those which are progressive in nature are likely to have metastasized by the time of detection. Survival rates for individuals with metastatic prostate cancer are quite low. Between these extremes are patients with prostate tumors that will metastasize but have not yet done so, for whom surgical prostate removal is curative. Determination of which group a patient falls within is critical in determining optimal treatment and patient survival.
  • allelic loss (Bova, et al, 1993; Macoska et al, 1994; Carter et al, 1990); DNA hypermethylation (Isaacs et al, 1994); point mutations or deletions of the retinoblastoma (Rb) and p53 genes (Bookstein et al, 1990a; Bookstein et al, 1990b; Isaacs et al, 1991); and aneuploidy and aneusomy of chromosomes detected by fluorescence in situ hybridization (FISH) (Macoska et al. , 1994; Visakorpi et al. , 1994; Takahashi et al. , 1994; Alcaraz et al. , 1994).
  • FISH fluorescence in situ hybridization
  • KAI1 prostate metastasis suppresser gene
  • PSA serum prostate specific antigen
  • PAP prostatic acid phosphatase
  • PSP prostate secreted protein
  • PAP is secreted by prostate cells under hormonal control (Brawn et al. , 1996). It has less specificity and sensitivity than does PSA. As a result, it is used much less now, although PAP may still have some applications for monitoring metastatic patients that have failed primary treatments.
  • PSP is a more sensitive biomarker than PAP, but is not as sensitive as PSA (Huang et al, 1993). Like PSA, PSP levels are frequently elevated in patients with BPH as well as those with prostate cancer.
  • PSMA prostate specific membrane antigen
  • Type II cell membrane protein has been identified as Folic Acid Hydrolase (FAH) (Heston, 1996; Carter et al, 1996). Antibodies against PSMA react with both normal prostate tissue and prostate cancer tissue (Horoszewicz et al, 1987). Murphy et al. (1995) used ELISA to detect serum PSMA in advanced prostate cancer. As a serum test, PSMA levels are a relatively poor indicator of prostate cancer. However, PSMA may have utility in certain circumstances. PSMA is expressed in metastatic prostate tumor capillary beds (Silver et al, 1997) and is reported to be more abundant in the blood of metastatic cancer patients (Murphy et al, 1996).
  • PSMA messenger RNA is down-regulated 8-10 fold in the LNCaP prostate cancer cell line after exposure to 5- ⁇ -dihydroxytestosterone (DHT) (Israeli et al, 1994).
  • DHT 5- ⁇ -dihydroxytestosterone
  • a relatively new potential biomarker for prostate cancer is human kallekrein 2 (HK2) (Piironen et al, 1996).
  • HK2 is a member of the kallekrein family that is secreted by the prostate gland.
  • serum concentrations of HK2 may be of utility in prostate cancer detection or diagnosis, but the usefulness of this marker is still being evaluated.
  • Interleukin 8 is a potent serum cytokine that is synthesized and secreted by a large variety of cell types, including neutrophils, endothelial cells, T-cells, macrophages, monocytes, and fibroblasts (Saito et al. , 1994). Previous reports have found overexpression of IL-8 in some forms of cancer, (di Celle et al, 1994; Ikei et al, 1992; Scheibenbogenet al, 1995; Vinante et al, 1993). RT-PCR analysis was used by di Celle et al. (1994) to demonstrate IL-8 production in B- cell chronic lymphocytic leukemia.
  • Vinante et al (1993) used Northern blot analysis to show upregulation of IL-8 expression in acute myelogenous leukemia.
  • Ikei et al. (1992) found an increase in serum levels of IL-8 in hepatic cancer patients following therapeutic treatment.
  • Scheibenbogen et al. (1995) observed a correlation between IL-8 levels and tumor loads in patients with metastatic melanoma, while reporting that serum IL-8 was undetectable in healthy individuals or in patients with metastatic renal cell carcinoma. These authors suggested that the IL-8 was produced by the melanoma cells themselves, rather than by circulating lymphocytes.
  • Andrawis et al. (1996) reported that while IL-8 was expressed in prostate and bladder cancer, it was also abundantly expressed in normal bladder epithelium and in some basal cells in BPH.
  • the instant disclosure is the first to combine measurement of IL-8 gene products with serum markers of prostate disease, such as PSA, PAP, HK2 or PSMA.
  • serum markers of prostate disease such as PSA, PAP, HK2 or PSMA.
  • the present invention addresses deficiencies in the prior art by providing methods for identifying specific disease state markers that are expressed in peripheral lymphocytes of patients in response to a disease state, at a different level than such markers are expressed in the peripheral blood of a normal subject (a healthy individual).
  • An important advantage provided by the present invention is that a disease state may be detected, diagnosed, or a prognosis may be derived by examining a blood sample rather than relying on a more invasive, or less sensitive test.
  • a subject may be monitored for disease progression, status and response to therapies through monitoring of differentially expressed disease markers.
  • a "patient” "individual” or “subject” may be an animal, including a laboratory animal or other animal species, or in certain embodiments a human subject.
  • the terms “expression”, “gene expression” and “expression products” may refer to either production of a marker gene RNA message or the RNA message produced or both. In certain other embodiments of the invention the terms “expression”, “gene expression” and “expression products” may refer to either translation of a marker RNA message into proteins, polypeptides and/or peptides, and/or to the produced proteins, polypeptides, and/or peptides. In certain aspects of the invention a marker may be a gene whose expression is activated to a higher level in a patient suffering a disease state, relative to its expression in a healthy subject.
  • a differentially expressed marker may be either activated or inhibited at the nucleic acid level or protein level, or may it may subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a change in mRNA levels, surface expression, secretion or other partitioning of a polypeptide, for example.
  • a marker may be a comparison of expression between two or more marker genes, and/or a comparison of the ratios of the expression between two or more marker genes, or even a comparison of two differently processed products of the same gene, which differ between healthy subjects and subjects suffering a diseased state.
  • the present inventors have identified certain markers and methods of identifying markers that have been applied for the detection of metastatic prostate and metastatic breast cancer. These examples have demonstrated that disease states may be detected and monitored by surveying the response of healthy immune cells to the disease condition. As such, this novel method is contemplated to be suitable for detection of markers that are differentially expressed in response to other forms of cancer as well as other diseases such as asthma, lupus erythematosis, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, autoimmune thyroiditis, amyloid lateral sclerosis, interstitial cystitis, prostatitis or other systemic or chronic conditions.
  • diseases such as asthma, lupus erythematosis, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, autoimmune thyroiditis, amyloid lateral sclerosis, interstitial cystitis, prostatitis or other systemic or chronic conditions.
  • the inventors have demonstrated the ability to detect and discriminate between benign prostatic hyperplasia (BPH) and prostate cancer, using multivariate analysis with several different prostate disease markers.
  • BPH benign prostatic hyperplasia
  • PSA serum prostate specific antigen
  • IL-8 gene products
  • mRNAs are identified that are differentially expressed in normal cells, as a reaction to a disease state, relative to their expression in healthy subjects.
  • Two of the metastatic cancer-markers disclosed herein represent previously unreported genes, with one of the two matching a small expressed sequence tag (EST) described in Genebank Accession # T03013 and SEQ ID NO : 1 , and another matching the sequence disclosed in SEQ ID NO:2.
  • EST small expressed sequence tag
  • Another marker corresponds to the sequence of elongation factor 1- alpha (Genebank Accession # X03558 and SEQ ID NO: 3).
  • Two other markers represent alternatively spliced forms (Genebank Accession # M28130 and SEQ ID NO:5; Genebank Accession # Y00787 and SEQ ID NO:4) of mRNA from the IL-8 (interleukin 8) gene.
  • One metastatic cancer marker is a previously uncharacterized gene (SEQ ID NO:29) that has homology to a number of previously identified EST sequences, while another marker is a previously identified gene sequence (KA000262, Genebank Accession # D87451).
  • differential expression of marker genes is detected by RNA fingerprinting methods, however, differential expression detected by any other means, including but not limited to other RNA fingerprinting methods, Northern blotting, immunodetection, protein-protein interactions, biological activity or other methods known in the art would fall within the scope of the present invention.
  • the present disclosure is the first report of an alternatively spliced form of IL-8 mRNA that includes intron 3.
  • the mRNA transcript containing intron 3 (Genebank Accession # M28130) is more abundant than the previously reported spliced form from which intron 3 is missing (Genebank Accession # Y00787).
  • the previously reported spliced form is much more abundant, with a seven-fold increase compared to normal individuals.
  • the transcript containing intron 3 is approximately seven-fold less abundant in patients with metastatic prostate cancer than in normal individuals.
  • metastatic cancer detection and diagnosis may be performed by quantitative analysis of either the IL-8 mRNA transcripts themselves or their protein products.
  • the present disclosure represents a substantial and unexpected advance over previous knowledge in this field. It reports a novel spliced form of IL-8 mRNA that is repressed in metastatic prostate cancer. It provides a sensitive means for detecting metastatic cancer by measuring the levels of the two alternatively spliced IL-8 mRNA forms. It provides a highly sensitive and specific method for detecting and differentiating between BPH, localized and advanced forms of prostate cancer by combining detection of IL-8 gene product with other markers of prostate disease.
  • the present disclosure further demonstrates the feasibility of detecting and diagnosing human disease states in general by monitoring changes in the expression of specific genes in peripheral lymphocytes.
  • the skilled practitioner of the art will realize that such a technique has widespread applicability for screening of asymptomatic individuals for disease state markers.
  • the identified disease state markers may in turn be used to design specific oligonucleotide probes and primers.
  • the term "primer" as used here includes any nucleic acid capable of priming template-dependent synthesis of a nascent nucleic acid.
  • the nucleic acid may be able to hybridize a template, but not be extended for synthesis of nascent nucleic acid that is complementary to the template.
  • a "primer" may be at least about 5, about 6, about 7, about 8, about 9, about 10, about 1 1, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 35, about 40, about 50, about, 75, about 100, about 150, about 200, about 300, about 400, about 500, to one base shorter in length than the template sequence at the 3 ' end of the primer to allow extension of a nascent nucleic acid chain, though the 5' end of the primer may extend in length beyond the 3' end of the template sequence.
  • the term "template” may refer to a nucleic acid that is used in the creation of a complementary nucleic acid strand to the "template” strand.
  • the template may be either RNA and/or DNA, and the complementary strand may also be
  • the complementary strand may comprise all or part of the complementary sequence to the template, and/or may include mutations so that it is not an exact, complementary strand to the template. Strands that are not exactly complementary to the template strand may hybridize specifically to the template strand in detection assays described here, as well as other assays known in the art, and such complementary strands that can be used in detection assays are part of the invention.
  • the term “amplification” may refer to any method or technique known in the art or described herein for duplicating or increasing the number of copies or amount of a target nucleic acid or its complement.
  • the term “amplicon” refers to the target sequence for amplification, or that part of a target sequence that is amplified, and/or the amplification products of the target sequence being amplified.
  • an "amplicon” may include the sequence of probes or primers used in amplification. This analysis assists physicians in detecting and diagnosing the disease state and in determining optimal treatment courses for individuals at varying stages of disease state progression.
  • Marker gene sequences include those published in the Genebank database that match the identified marker genes: Genebank Accession numbers D87451, T03013, X03558, M28130, and Y00787, as well as the sequences disclosed herein as SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:29, which also include sequences for previously uncharacterized marker genes (UCPB 35, SEQ ID NO:l ; UC 302, SEQ ID NO:2; UC 331, SEQ ID NO:29) identified herein.
  • the sequences selected to design probes and primers may include repetitive stretches of adenine nucleotides (poly- A tails) normally attached at the ends of the RNA for the identified marker genes.
  • probes and primers may be specifically designed to not include these or other segments from the identified marker genes, as one of ordinary skilled in the art may deem certain segments more suitable for use in the detection methods disclosed.
  • At least one metastatic cancer marker includes alternately spliced transcripts so that intronic sequences may be used for diagnostic or prognostic purposes (Genebank Accession # M28130).
  • Exon sequences in the gene structure include bases 1482 to 1647, 2464 to 2599, 2871 to 2954, and 3370 to 4236.
  • Intron 3 includes bases 2954 to 3370.
  • One of ordinary skill in the art may select segments from the published exon sequences, or may assemble them into a reconstructed mRNA sequence that does not contain intronic sequences, such as intron 3.
  • the published sequence for IL-8 that reports a spliced form from which intron 3 is missing may be used.
  • the sequences to include or exclude intron 3 one could preferentially detect expression of one alternatively spliced form of IL-8, or even the ratio of the two forms using the methods disclosed herein.
  • One of ordinary skill in the art may select and/or assemble segments from any of the identified marker gene sequences into other useful forms, such as coding segment reconstruction's of mRNA sequences from published genomic sequences of the identified marker genes, as part of the present invention.
  • primers to detect the message of IL 8 using the transcribed portions of the marker sequence as set forth in the listing in Genebank Accession # M28130 may hybridize to nucleotides 1482 to 1503 and the complement of nucleotides 1626-1647. These particular primers would amplify a segment of message of the marker gene 166 base pairs in length.
  • Primers designed to nucleotides 1482 to 1503 and the complement of nucleotides 2464 to 2483 would amplify a segment of message of the marker gene 186 base pairs long in messages that have the intervening intron between nucleotides 1648 to 2463 removed.
  • one skilled in the art would be able to calculate the expected size of transcribed sequences from marker genes identified herein whose sequences are published either as genomic sequence, mRNA, or cDNA, as well as the sequences disclosed herein, taking into account the differences in size of the products produced depending on the presence or absence of intronic sequences.
  • the differences in size of amplification products using primers designed to regions flanking both sides of intron 3 in the IL-8 marker gene sequences identified can be used in detection, diagnosis, and/or prognosis of metastatic cancer.
  • primers designed to regions of IL-8 sequences that do not flank intron 3, or the other marker genes that do not have differences in intron splicing, or that prime mRNA or cDNA template sequences would not be expected to produce amplification products that include intronic segments.
  • primers designed to nucleotides 1 to 20 and the complement of nucleotides 200 to 220 of SEQ ID NO: 1 would amplify a metastatic marker gene segment 220 base pairs long.
  • Primers designed to nucleotides 1 15 to 138 and the complement of nucleotides 730 to 744 of SEQ ID NO:29 would amplify a metastatic marker gene segment 630 base pairs long.
  • Primers designed to nucleotides 102 to 120 and the complement of nucleotides 381 to 401 of the IL-8 marker gene sequence identified in Genebank Accession # Y00787 would amplify a metastatic marker gene segment 302 base pairs long that would be approximately sevenfold less abundant in normal patients when compared to patients with metastatic prostate cancer.
  • Primers can be designed to amplify the transcribed portions of the metastatic cancer markers that would include any length of nucleotide segment of the transcribed sequences, up to and including the full length of each marker gene message. It is preferred that the amplified segments of identified marker genes be an amplicon of at least about 50 to about 500 base pairs in length. It is particularly preferred that the amplified segments of identified marker genes be an amplicon of at least about 100 to about 415 base pairs in length, and/or no longer in length than the amplified segment used to normalize the quantity of message being amplified in the detection assays described herein. Such assays include RNA fingerprinting methods, however, differential expression may be detected by other means, and all such methods would fall within the scope of the present invention.
  • the predicted size of the amplified metastatic cancer marker gene segment calculated by the location of the primers relative to the transcribed sequence, would be used to determine if the detected amplification product is indeed the marker gene being amplified. Sequencing the amplified or detected band that matches the expected size of the amplification product and comparison of the band's sequence to the known or disclosed sequence of the marker gene would confirm that the correct marker gene is being amplified and detected.
  • the identified markers may also be used to identify and isolate full length gene sequences, including regulatory elements for gene expression, from genomic human DNA libraries.
  • the cDNA sequences identified in the present disclosure may be used as hybridization probes to screen genomic human DNA libraries by conventional techniques. Once partial genomic clones have been identified, full-length genes may be isolated by "chromosomal walking" (also called “overlap hybridization”). See, Chinault & Carbon "Overlap Hybridization Screening: Isolation and
  • the identified markers may be used to identify and isolate cDNA sequences.
  • the EST sequences identified in the present disclosure may be used as hybridization probes to screen human cDNA libraries by conventional techniques. It will be recognized that these techniques would start by obtaining a high quality human cDNA library, many of which are readily available from commercial or other sources.
  • the library may be plated on, for example, agarose plates containing nutrients, antibiotics and other conventional ingredients. Individual colonies may then be transferred to nylon or nitrocellulose membranes and the EST probes hybridized to complementary sequences on the membranes. Hybridization may be detected by radioactive or enzyme-linked tags associated with the hybridized probes. Positive colonies may be grown up and sequenced by, for example, Sanger dideoxynucleotide sequencing or similar methods well known in the art.
  • Comparison of cloned cDNA sequences with known human or animal cDNA or genomic sequences may be performed using computer programs and databases well known in the art. Sequences identified and isolated by such means may be useful in the detection of the prostate disease, or other disease marker genes using the detection methods described herein, and are part of the invention.
  • the isolated nucleic acids of the identified marker genes are incorporated into expression vectors and expressed as the encoded proteins or peptides.
  • Isolated nucleic acid segments may be from published sequences identified, or the sequences disclosed herein, as marker genes. Coding sequences may be assembled from amino acid encoding segments of marker genes to remove noncoding segments, or to truncate coding sequence, or to use the coding sequences or segments thereof in expression vectors as is known in the art.
  • genomic sequences may be used to express peptides or proteins of the metastatic cancer maker genes identified herein.
  • Such proteins or peptides are in turn used as antigens for induction of monoclonal or polyclonal antibody production.
  • Such antibodies may in turn be used to detect expressed proteins as additional markers for human disease states.
  • Antibody-protein binding may be detected and quantitated by a variety of means known in the art, such as labeling with fluorescent or radioactive ligands.
  • Certain metastatic marker genes disclosed herein do not have reading frames for translation disclosed. However, one of ordinary skill in the art may translate the identified sequences or segments thereof in the three potential reading frames to obtain peptides or proteins for use in generating antibodies to these marker genes. Such antibodies may be used to purify the proteins of the marker genes, and the identity of protein being detected is confirmed by peptide sequencing of the protein. Once confirmed as binding the translation products of the marker genes corresponding to SEQ ID NO: 1 and Genebank accession # T03013, and/or SEQ ID NO:2, the antibodies that bind the marker gene protein would be useful in detecting, diagnosis, or prognosis of metastatic cancer.
  • marker gene sequence that would be preferred for translation would be intron 3 of IL-8 (Genebank Accession # M28130). Peptides or polypeptides that contain amino acid sequences from this intron would be preferred in the creation of polyclonal or monoclonal antibodies that preferentially detect forms of IL-8 which include intron 3.
  • the terms “immunodetection”, “immunobinding”, “immunoreaction”, “immunohistochemical”, “immunosorbent”, and “radioimmunoassays” refers to methods that concern binding, purifying, removing, quantifying or otherwise generally detecting biological components by obtaining a sample suspected of containing a protein, peptide or antibody, and contacting the sample with an antibody or protein or peptide in accordance with the present invention, as the case may be, under conditions effective to allow the formation of immunocomplexes.
  • the steps of various useful immunodetection methods have been described in the scientific literature, such as, e.g., Nakamura et al. (1987).
  • the aforementioned oligonucleotide hybridization probes and primers are specific for disease state markers comprising isolated nucleic acids of a sequence comprising the sequences published in Genebank Accession numbers D87451 , T03013, X03558, M28130, and Y00787, as well as the sequences disclosed herein as SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:29.
  • probes and primers may be of any length that would specifically hybridize to the identified marker gene sequences and may be at least about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21 , about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30, about 35, about 40, about 50, about, 75, about 100, about 150, about 200, about 300, about 400, about 500, and in the case of probes, up to the full length of the sequences of the marker genes identified herein. Probes may also include additional sequence at their 5' and/or 3' ends so that they extend beyond the target sequence with which they hybridize. Such primers may be used to amplify disease state markers present in a biological sample, such as peripheral human blood.
  • Amplification increases the sensitivity of various known techniques for detecting the presence of nucleic acid markers for human disease.
  • Probes that hybridize with nucleic acid markers for human disease may be detected by conventional labeling methods, such as binding of fluorescent or radioactive ligands.
  • the availability of probes and primers specific for such unique markers provides the basis for diagnostic kits identifying disease state progression.
  • An embodiment of the present invention encompasses a kit for detecting a disease state in a biological sample, comprising pairs of primers for amplifying nucleic acids corresponding to the marker genes and containers for each of these primers.
  • the invention encompasses a kit for detecting a disease state in a biological sample, comprising oligonucleotide probes that bind with high affinity to markers of the disease state and containers for each of these probes.
  • the invention encompasses a kit for detecting a disease state in a biological sample, comprising antibodies specific for proteins encoded by the nucleic acid markers of the disease state identified in the present invention.
  • the present invention comprises an isolated nucleic acid of a sequence comprising SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:29, and the sequences identified in Genebank Accession #s D87451, T03013, X03558, M28130, and Y00787.
  • the invention further broadly comprises an isolated nucleic acid of between 17 and 100 bases in length, either identical to or complementary with portions of the above mentioned isolated nucleic acids.
  • Such isolated nucleic acids may themselves be used as probes for human disease markers, or may be used to design probes and primers specific for disease state markers.
  • the invention further broadly comprises an isolated nucleic acid of between 17 bases to the full sequence length, either identical to or complementary with portions of the above mentioned isolated nucleic acids.
  • the present invention comprises proteins and peptides with amino acid sequences encoded by the aforementioned isolated nucleic acids. The proteins and peptides may be directly detected in the practice of the invention, or used for antibody production.
  • the invention also broadly comprises methods for identifying biomarkers for use in prognostic or diagnostic assays of a disease state, using the technique of RNA fingerprinting to identify RNAs that are differentially expressed between individuals with the disease state versus normal individuals.
  • RNA fingerprinting to identify RNAs that are differentially expressed between individuals with the disease state versus normal individuals.
  • promiscuous oligonucleotide primers denotes oligonucleotides that are statistically designed to sample sequence complexity in mRNAs, or open reading frames of mRNAs without bias as applied in a PCR based RNA fingerprinting technique.
  • the use of promiscuous primers is preferred because such use increases the sampling rate of RNA for fingerprinting by increasing the displayed fingerprint complexity. This increases the rate at which differentially expressed mRNAs can be discovered.
  • the use of promiscuous oligonucleotide primers as disclosed herein will be evident to one of skill in the art in light of the publication by Lopez-Nieto and Nigam, Nature Biotechnology 14:857-861, 1996, (incorporated in pertinent part herein by reference).
  • random hexamers or “small random oligonucleotides” refer to primers of random or semi-random nucleotide sequence of about 6 bases in length, though in certain embodiments the length of the primers may be of any length previously described for "primers”.
  • “arbitrarily chosen oligonucleotides” may refer to primers that are selected at the discretion of one skilled in the art, and may be of random or nonrandom sequence. In certain other embodiments “arbitrarily chosen oligonucleotides” may refer to primers as described by Welsh et al, 1992, incorporated herein by reference.
  • Oligonucleotide sequences designed to bind to specific genes, IL-8 or PSA for example, may also be used in the practice of this method.
  • the present invention may be described in a broad aspect as a method for identifying serological markers for a human disease state.
  • the method comprises the steps of providing human peripheral blood mRNAs; amplifying the mRNAs to provide nucleic acid amplification products; separating the nucleic acid amplification products; and identifying those mRNAs that are differentially expressed between normal individuals and individuals exhibiting a disease state.
  • the described method may also comprise, in certain embodiments, the step of converting the RNAs into cDNAs using reverse transcriptase to detect and quantitate circulating cells induced by the disease state.
  • RNA into cDNAs using reverse transcriptase is referred to as a "reverse transcriptase" reaction.
  • reverse transcriptase Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook et al, 1989.
  • RNA-dependent DNA polymerases Alternative methods for reverse transcription utilize thermostable, RNA-dependent DNA polymerases. These methods are described in WO 90/07641, filed December 21, 1990, incorporated herein by reference.
  • a "reverse transcriptase" reaction refers to additional steps of amplification of the RNA template or its cDNA product. Such step of amplification may include any methods known in the art of increasing the number of copies of RNA or DNA, as well as the methods described herein. Methods of amplification include the methods described in Davey et al, EPA No.
  • 329 822 (incorporated herein by reference in its entirely) , as well as polymerase chain reaction or ligase chain reaction
  • diseases include, but are not limited to metastatic or organ defined cancer, particularly metastatic prostate or breast cancer, asthma, lupus erythematosis, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, autoimmune thyroiditis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), interstitial cystitis or prostatitis.
  • diseases include, but are not limited to metastatic or organ defined cancer, particularly metastatic prostate or breast cancer, asthma, lupus erythematosis, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, autoimmune thyroiditis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), interstitial cystitis or prostatitis.
  • the invention further broadly comprises methods for detecting a disease state in biological samples, using nucleic acid amplification techniques with primers and hybridization probes selected to bind specifically to an isolated nucleic acid of a sequence comprising SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:4, SEQ ID NO:2 and SEQ ID NO:29 and the sequences identified in Genebank Accession #s D87451, T03013, X03558, M28130, and Y00787, thereby measuring the amounts of nucleic acid amplification products formed.
  • the invention further broadly comprises the prognosis and/or diagnosis of a disease state by measuring the amounts of nucleic acid amplification products formed.
  • the amounts of nucleic amplification products identified in an individual patient may be compared with groups of normal individuals or individuals with an identified disease state. Diagnosis may be accomplished by finding that the patient's levels of disease state markers fall within the normal range, or within the range observed in individuals with the disease state. Further comparison with groups of individuals of varying disease state progression, such as metastatic vs. non-metastatic cancer, may provide a prognosis for the individual patient.
  • the invention further broadly comprises kits for performing the above-mentionedprocedures, containing amplification primers and/or hybridization probes.
  • the invention may be described therefore, in certain broad aspects as a method of detecting a human disease state, comprising the steps of detecting the quantity of a disease marker expressed in human peripheral blood and comparing the quantity of the said marker to the quantity expressed in peripheral blood of a normal individual, where a difference in quantity of expression is indicative of a disease state.
  • the disease marker may preferably be an mRNA, or even an mRNA amplified by an RNA polymerase reaction, for example.
  • the mRNA may also be amplified by any other means such as reverse transcriptase polymerase chain reaction or the ligase chain reaction.
  • RNA may be detected by any means known in the art, such as by RNA fingerprinting, branched DNA or a nuclease protection assay, for example.
  • Disease states that may be detected by the present method include any disease state for which a marker is known and may include metastatic cancer, particularly metastatic prostate cancer, asthma, lupus erythromatosis, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, autoimmune thyroiditis, amyotrophic lateral sclerosis, interstitial cystitis or prostatitis.
  • the mRNA will comprise one or more of the sequences or the complements of the transcribed sequences disclosed herein as SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:29 and the sequences identified in Genebank Accession #s D87451, T03013, X03558, M28130, and Y00787, or the mRNA may comprise a product of the interleukin 8 (IL-8) gene.
  • IL-8 interleukin 8
  • the method of detecting a disease state described in the previous paragraphs may further comprise the steps of providing primers that selectively amplify the disease state marker, amplifying the nucleic acid with said primers to form nucleic acid amplification products, detecting the nucleic acid amplification products and measuring the amount of the nucleic acid amplification products formed.
  • the primers may be selected to specifically amplify a nucleic acid having a sequence comprising SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:29 and the sequences identified in Genebank Accession #s D87451, T03013, X03558, M28130, and Y00787.
  • the marker may be a polypeptide, and may even be a polypeptide encoded by a nucleic acid sequence comprising a sequence disclosed herein as SEQ
  • Detection of the disease state may be by detection of an antibody immunoreactive with said marker. It is also an embodiment of the invention that detection may be by a cellular bioassay, that responds to the presence of a biologically active agent such as IL-8, for example.
  • a "bioassay” is any assay that measures or detects the presence of a compound or effector, such as a protein, polypeptide, or peptide product of an expressed marker gene, by its affect on a cell, organism, or biologically derived reagent or detection system.
  • Bioassays that may be used in the present invention, include, but are not limited to, those described in Schroder et al, 1990 and Yoshimura et al, 1989, Kurdowska et al., 1997, Hedges et al., 1996, (all incorporated herein by reference), and all bioassays known in the art that can be used to detect the expressed markers.
  • the present invention broadly comprises production of antibodies specific for proteins or peptides encoded by SEQ ID NO: 1 , SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:4, SEQ ID NO:2,
  • SEQ ID NO:29 and the sequences identified in Genebank Accession #s D87451 , T03013, X03558, M28130, and Y00787, and the use of those antibodies for diagnostic applications in detecting and diagnosing the disease state.
  • the levels of such proteins present in the peripheral blood of a patient may be quantitated by conventional methods. Correlation of protein levels with the presence of a human disease or the progression of a human disease may be accomplished as described above for nucleic acid markers of human disease.
  • Another broad aspect of the present invention comprises the detection and diagnosis of disease states, including BPH and prostate cancer, by combining measurement of levels of two or more disease state markers.
  • a broad embodiment of the invention comprises combining measurement of serum IL-8 gene product with other markers of prostate disease, such as PSA, PAP, HK2, PSP 94 and PSMA.
  • kits for detection and measurement of the levels of two or more disease state markers in biological samples may incorporate a variety of methodologies for detection and measurement of disease state markers, including but not limited to oligonucleotide probes, primers for nucleic acid amplification, antibodies which bind specifically to protein products of disease state marker genes, and other proteins or peptides which bind specifically to disease state marker gene products.
  • FIG. IA Relative quantitative RT-PCR of UC Bands #325-1 (intron 3-) and 325-2 (intron 3+) shows that the normally spliced form of IL-8 mRNA (intron 3-) is abundantly expressed in individuals with metastatic prostate cancer (M) compared with normal individuals (N). The amplification reactions were sampled at different cycle numbers. The alternatively spliced form of IL-8 mRNA (intron 3+) is more abundant in normal individuals than in patients with metastatic cancer. The data were normalized against ⁇ -actin mRNA.
  • FIG. IB Relative quantitative RT-PCR of UC Bands #325-1 (intron 3-) and 325-2 (intron 3+) shows that the normally spliced form of IL-8 mRNA (intron 3-) is abundantly expressed in individuals with metastatic prostate cancer (M) compared with a pool of normal individuals (N). The alternatively spliced form of IL-8 mRNA (intron 3+) is more abundant in normal individuals than in patients with metastatic cancer. The data were normalized against ⁇ - actin mRNA.
  • FIG. 2. Ability of total PSA (t-PSA) to distinguish BPH and Stages A, B, & C prostate cancer.
  • FIG. 3 Ability of corrected free/total PSA (f/t PSA) ratio to distinguish BPH and Stages A, B, & C prostate cancer.
  • FIG. 4 Ability of UC325 (IL-8) to distinguish BPH and Stages A, B, & C prostate cancer.
  • FIG. 5 Ability of UC325 (IL-8) and t-PSA combined to distinguish BPH and Stages A,
  • FIG. 6 Ability of UC325 (IL-8) and the f/t PSA ratio combined to distinguish BPH and Stages A, B, & C prostate cancer.
  • FIG. 7 Relative quantitative RT-PCRTM showing that UC331 mRNA is roughly seven times more abundant in the peripheral blood of individuals with recurrent metastatic breast or prostate cancer compared to UC331 mRNA levels from healthy volunteers.
  • PCRTM amplification of a UC331 specific cDNA fragment was performed using the same pools of ⁇ -actin normalized cDNAs as templates. PCRTM reactions were terminated after either 25, 28 or 31 cycles. Pools of cDNAs were constructed from peripheral blood RNAs from eight healthy volunteers (N), ten individuals with recurrent metastatic prostate cancer (P), or ten individuals with recurrent metastatic breast cancer (B).
  • the intensity of the bands are proportional to the relative amounts of UC331 mRNA in the individuals from which these cDNA pools were constructed.
  • FIG. 8 PCRTM amplification of a UC332 specific cDNA fragment using the same pools of normalized cDNAs as templates. PCRTM reactions were terminated after either 25, 28 or 31 cycles. Pools of cDNAs were constructed from peripheral blood RNAs from eight healthy volunteers (N), ten individuals with recurrent metastatic prostate cancer (P), or ten individuals with recurrent metastatic breast cancer (B). The intensity of the bands are proportional to the relative amounts of UC332 mRNA in the individuals from which these cDNA pools were constructed.
  • PAP prostatic acid phosphatase
  • PSA prostate specific antigen
  • PSMA prostate specific membrane antigen (Folic Acid Hydrolase)
  • PSP 94 prostate secreted protein (94 kDa)
  • t-PSA total PSA
  • f/t Free/Total PSA
  • IL-8 Interleukin-8 (UC 325)
  • SENSITIVITY (True Positives/(True Positives + False Negatives); plotted on y-axis of ROC curve.
  • SPECIFICITY (True Negatives)/(True Negatives + False Positives); plotted on x-axis (as 1-
  • ROC Receiver Operator Character Curve; a means of plotting sensitivity and specificity over a range of cut-off (threshold) values.
  • BPH benign prostate hyperplasia (or hypertrophy)
  • CaP adenocarcinoma of the prostate
  • Stage A CaP organ-confined clinical stage of prostate cancer in which tumor is not palpable by a digital rectal exam (DRE) (Walsh & Worthington, 1995).
  • Stage B CaP organ-confined clinical stage of prostate cancer in which tumor is palpable by a digital rectal exam and involves one or both lobes of the gland
  • Stage C CaP non-organ-confined clinical stage of prostate cancer in which tumor is palpable by a DRE and invades beyond the capsule and/or the seminal vesicles (Walsh & Worthington, 1995).
  • Stage D CaP non-organ-confined clinical stage of prostate cancer characterized by metastases to lymph nodes, bone or other distant organ site (Walsh &
  • the present invention concerns the early detection, diagnosis, and prognosis of human disease states.
  • Markers of a disease state in the form of isolated nucleic acids of specified sequences from the peripheral blood of individuals with the disease state, are disclosed. These markers are indicators of the disease state and are diagnostic for the presence of the disease state in patients. Such markers provide considerable advantages over the prior art in this field. Since they are detected in peripheral blood samples, it is not necessary to suspect that an individual exhibits the disease state before a sample may be taken. The detection methods disclosed are thus suitable for widespread screening of asymptomatic individuals. Further, the methods provide for sensitive detection of disease state markers that is relatively unaffected by the presence of normal, non- diseased cells in a biological sample such as peripheral blood.
  • nucleic acid sequences disclosed will find utility in a variety of applications in disease state detection, diagnosis, prognosis and treatment.
  • applications within the scope of the present disclosure comprise amplification of markers of the disease state using specific primers, detection of markers of the disease state by hybridization with oligonucleotide probes, incorporation of isolated nucleic acids into vectors, expression of vector- incorporated nucleic acids as RNA and protein, and development of immunologic reagents corresponding to marker encoded products.
  • UC-325 (IL-8) serology in combination with PSA and f/t PSA can more accurately differentially diagnose prostate cancer and BPH. This method provides significant advantages over previous methodologies for detecting prostatic cancer, which often failed to differentiate between prostatic cancer and BPH.
  • Nucleic Acids As described in Examples 1 through 4, the present disclosure provides five markers of a disease state, identified by RNA fingerprinting. These include two previously previously uncharacterized gene products, as well as nucleic acid products of the IL-8 (interleukin 8) and human elongation factor 1 -alpha genes.
  • the sequences of isolated nucleic acids disclosed herein find utility as hybridization probes or amplification primers. These nucleic acids may be used, for example, in diagnostic evaluation of tissue samples or employed to clone full length cDNAs or genomic clones corresponding thereto.
  • these probes and primers comprise oligonucleotide fragments. Such fragments are of sufficient length to provide specific hybridization to an RNA or DNA sample extracted from tissue.
  • the sequences typically will be 10-20 nucleotides, but may be longer. Longer sequences, e.g. , 40, 50, 100, 500 and even up to full length, are preferred for certain embodiments.
  • Nucleic acid molecules having contiguous stretches of about 10, 15, 17, 20, 30, 40, 50, 60, 75 or 100 or 500 nucleotides of a sequence comprising Genebank Accession numbers D87451, T03013, X03558, M28130, Y00787, SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:29 are contemplated.
  • Molecules that are complementary to the above mentioned sequences and that bind to these sequences under high stringency conditions are also contemplated. These probes are useful in a variety of hybridization embodiments, such as Southern and northern blotting. In some cases, it is contemplated that probes may be used that hybridize to multiple target sequences without compromising their ability to effectively diagnose the disease state.
  • n to n + y where n is an integer from 1 to the last number of the sequence and y is the length of the primer minus one (9 to 19), where n + y does not exceed the last number of the sequence.
  • the probes correspond to bases 1 to 10, 2 to 1 1 , 3 to 12 ... and so on.
  • the probes correspond to bases 1 to 15, 2 to 16, 3 to 17 ... and so on.
  • the probes correspond to bases 1 to 20, 2 to 21, 3 to 22 ... and so on.
  • multiple probes may be used for hybridization to a single sample.
  • an alternatively spliced form of IL-8 mRNA, containing intron 3 may be detected by probing human tissue samples with oligonucleotides specific for intron 3 and for exon portions of the IL-8 transcript.
  • Hybridization with the intron 3 and exon sequences probe would be indicative of a normal individual and binding to only the exon probe would be indicative of metastatic prostate cancer.
  • the use of a hybridization probe of between 17 and 100 nucleotides in length allows the formation of a duplex molecule that is both stable and selective.
  • Molecules having complementary sequences over stretches greater than 20 bases in length are generally preferred in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of hybrid molecules. It is generally preferred to design nucleic acid molecules having stretches of 20 to 30 nucleotides, or even longer. Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means or by introducing selected sequences into recombinant vectors for recombinant production.
  • nucleic acid sequence is well known in the art and is based on the anti-parallel, Watson-Crick pairing of nucleotides (bases) for a given nucleic acid polymer (strand). Two complementary strands of DNA are formed into a duplex by pairing of bases, e.g.
  • the term “complement” defines a second strand of nucleic acid which will hybridize to a first strand of nucleic acid to form a duplex molecule in which base pairs are matched as G:C, C:G, A:T/U or T/U:A.
  • a complement may also be described as a fragment of DNA (nucleic acid segment) or a synthesized single stranded oligomer that may contain small mismatches or gaps when hybridized to its complement, but that is able to hybridize to the complementary DNA under high stringency conditions.
  • To hybridize is understood to mean the forming of a double stranded molecule or a molecule with partial double stranded nature.
  • High stringency conditions are those that allow hybridization between two homologous nucleic acid sequences, but precludes hybridization of random sequences. For example, hybridization at low temperature and/or high ionic strength is termed low stringency. Hybridization at high temperature and/or low ionic strength is termed high stringency.
  • Low stringency is generally performed at 0.15 M to 0.9 M NaCl at a temperature range of 20°C to 50°C.
  • High stringency is generally performed at 0.02 M to 0.15 M NaCl at a temperature range of 50°C to 70°C. It is understood that the temperature and ionic strength of a desired stringency are determined in part by the length of the particular probe, the length and base content of the target sequences, and to the presence of formamide, tetramethylammonium chloride or other solvents in the hybridization mixture. It is also understood that these ranges are mentioned by way of example only, and that the desired stringency for a particular hybridization reaction is often determined empirically by comparison to positive and negative controls.
  • nucleotide sequences of the disclosure may be used for their ability to selectively form duplex molecules with complementary stretches of genes or RNAs or to provide primers for amplification of DNA or RNA from tissues.
  • relatively stringent conditions For applications requiring high selectivity, it is preferred to employ relatively stringent conditions to form the hybrids.
  • relatively low salt and/or high temperature conditions such as provided by about 0.02 M to about 0.10 M NaCl at temperatures of about 50°C to about 70°C.
  • Such high stringency conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating specific genes or detecting specific mRNA transcripts. It is generally appreciated that conditions may be rendered more stringent by the addition of increasing amounts of formamide. For certain applications, for example, substitution of amino acids by site-directed mutagenesis, it is appreciated that lower stringency conditions are required.
  • hybridization may occur even though the sequences of probe and target strand are not perfectly complementary, but are mismatched at one or more positions.
  • Conditions may be rendered less stringent by increasing salt concentration and decreasing temperature.
  • a medium stringency condition may be provided by about 0.1 to 0.25 M NaCl at temperatures of about 37°C to about 55°C, while a low stringency condition may be provided by about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C.
  • hybridization conditions may be readily manipulated depending on the desired results.
  • the following codon chart may be used, in a site-directed mutagenic scheme, to produce nucleic acids encoding the same or slightly different amino acid sequences of a given nucleic acid:
  • hybridization may be achieved under conditions of, for example, 50 mM Tris-HCI (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, at temperatures between approximately 20°C to about 37°C.
  • Other hybridization conditions utilized may include approximately 10 mM Tris-HCI (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , at temperatures ranging from approximately 40°C to about 72°C.
  • indicator means include fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of being detected.
  • fluorescent label or an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents.
  • enzyme tags colorimetric indicator substrates are known which may be employed to provide a detection means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.
  • the hybridization probes described herein are useful both as reagents in solution hybridization, as in PCR, for detection of expression of corresponding genes, as well as in embodiments employing a solid phase.
  • the test DNA or RNA
  • the test DNA is adsorbed or otherwise affixed to a selected matrix or surface.
  • This fixed, single-stranded nucleic acid is then subjected to hybridization with selected probes under selected conditions.
  • the selected conditions depend on the particular circumstances based on the particular criteria required (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.).
  • hybridization is detected, or even quantified, by means of the label.
  • this disclosure is not limited to the particular probes disclosed herein and particularly is intended to encompass at least isolated nucleic acids that are hybridizable to nucleic acids comprising the disclosed sequences or that are functional sequence analogs of these nucleic acids.
  • a nucleic acid of partial sequence may be used to identify a structurally-related gene or the full length genomic or cDNA clone from which it is derived. Methods for generating cDNA and genomic libraries which may be used as a target for the above- described probes are known in the art (Sambrook et al. , 1989).
  • nucleic acid segments of the present disclosure are incorporated into vectors, such as plasmids, cosmids or viruses
  • these segments may be combined with other DNA sequences, such as promoters, polyadenylation signals, restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.
  • DNA segments encoding a specific gene may be introduced into recombinant host cells for expressing a specific structural or regulatory protein.
  • DNA segments encoding a specific gene may be introduced into recombinant host cells for expressing a specific structural or regulatory protein.
  • subportions or derivatives of selected genes may be employed.
  • Upstream regions containing regulatory regions such as promoter regions may be isolated and subsequently employed for expression of the selected gene.
  • nucleic acid sequence is varied while retaining the ability to encode the same product.
  • Reference to the codon chart, provided in Table 1 enables the design of any nucleic acid encoding the same protein or peptide product.
  • the gene may be inserted into an appropriate expression system.
  • the gene may be expressed in any number of different recombinant DNA expression systems to generate large amounts of the polypeptide product, which may then be purified and used to vaccinate animals to generate antisera which may also be useful in the practice of the disclosed invention.
  • polyclonal or monoclonal antibodies may be prepared that specifically bind to the protein product(s) of the marker-associated gene. Such antibodies may be incorporated into kits that may in turn be used for detection and diagnosis of the disease state in peripheral blood or other tissue samples.
  • polypeptides are expressed in E. coli and in baculovirus expression systems.
  • a complete gene may be expressed or, alternatively, fragments of the gene encoding portions of polypeptide may be produced.
  • the gene sequence encoding the polypeptide is analyzed to detect putative transmembrane sequences.
  • sequences are typically very hydrophobic and are readily detected by the use of sequence analysis software, such as Lasergene (DNAstar, Madison, WI).
  • sequence analysis software such as Lasergene (DNAstar, Madison, WI).
  • the presence of transmembrane sequences is often deleterious when a recombinant protein is synthesized in many expression systems, especially E. coli, as it leads to the production of insoluble aggregates that are difficult to renature into the native conformation of the protein. Deletion of transmembrane sequences typically does not significantly alter the conformation of the remaining protein structure.
  • transmembrane sequences being by definition embedded within a membrane, are inaccessible. Antibodies to these sequences will not prove useful for in vivo or in situ studies. Deletion of transmembrane-encoding sequences from the genes used for expression may be achieved by conventional techniques. For example, restriction enzyme sites may be used to excise the desired gene fragment, or PCR-type amplification may be used to amplify only the desired part of the gene.
  • computer sequence analysis is used to determine the location of predicted major antigenic determinant epitopes of the polypeptide.
  • Software capable of carrying out this analysis is readily available commercially.
  • Such software typically uses conventional algorithms such as the Kyte/Doolittle or Hopp/Woods methods for locating hydrophilic sequences which are characteristically found on the surface of proteins and are, therefore, likely to act as antigenic determinants.
  • polypeptides may be prepared which contain at least the essential features of the antigenic determinant and which may be employed in the generation of antisera against the polypeptide.
  • Minigenes or gene fusions encoding these determinants may be constructed and inserted into expression vectors by conventional methods, for example, using PCR cloning methodology.
  • a gene or gene fragment encoding a polypeptide may be inserted into an expression vector by conventional subcloning techniques.
  • an E. coli expression vector is used which produces the recombinant polypeptide as a fusion protein, allowing rapid affinity purification of the protein.
  • fusion protein expression systems are the glutathione S- transferase system (Pharmacia, Piscataway, NJ), the maltose binding protein system (NEB, Beverley, MA), the FLAG system (IBI, New Haven, CT), and the 6xHis system (Qiagen, Chatsworth, CA).
  • fusion systems produce polypeptide where it is desirable to excise the fusion partner from the desired polypeptide.
  • the fusion partner is linked to the recombinant polypeptide by a peptide sequence containing a specific recognition sequence for a protease. Examples of suitable sequences are those recognized by the Tobacco Etch Virus protease (Life Technologies, Gaithersburg, MD) or Factor Xa (New England Biolabs, Beverley, MA).
  • the expression system used is one driven by the baculovirus polyhedron promoter.
  • the gene encoding the polypeptide may be manipulated by conventional techniques in order to facilitate cloning into the baculovirus vector.
  • One baculovirus vector is the pBlueBac vector (Invitrogen, Sorrento, CA).
  • the vector carrying the gene for the polypeptide is transfected into Spodoptera frugiperda (Sf9) cells by conventional protocols, and the cells are cultured and processed to produce the recombinant antigen. See Summers et al, A MANUAL OF METHODS FOR BACULOVIRUS VECTORS AND INSECT CELL CULTURE PROCEDURES, Texas Agricultural Experimental Station; U.S. Patent No.
  • synthetic peptides corresponding to the antigenic determinants may be prepared.
  • Such peptides are at least six amino acid residues long, and may contain up to approximately 50 residues, which is the approximate upper length limit of automated peptide synthesis machines, such as those available from Applied Biosystems (Foster City, CA).
  • Use of such small peptides for vaccination typically requires conjugation of the peptide to an immunogenic carrier protein such as hepatitis B surface antigen, keyhole limpet hemocyanin or bovine serum albumin. Methods for performing this conjugation are well known in the art.
  • amino acid sequence variants of the polypeptide may be prepared. These may, for instance, be minor sequence variants of the polypeptide which arise due to natural variation within the population or they may be homologues found in other species. They also may be sequences which do not occur naturally but which are sufficiently similar that they function similarly and/or elicit an immune response that cross-reacts with natural forms of the polypeptide. Sequence variants may be prepared by conventional methods of site-directed mutagenesis such as those described above for removing the transmembrane sequence.
  • Amino acid sequence variants of the polypeptide may be substitutional, insertional or deletion variants.
  • Deletion variants lack one or more residues of the native protein which are not essential for function or immunogenic activity, and are exemplified by the variants lacking a transmembrane sequence described above.
  • Another common type of deletion variant is one lacking secretory signal sequences or signal sequences directing a protein to bind to a particular part of a cell.
  • An example of the latter sequence is the SH2 domain, which induces protein binding to phosphotyrosine residues.
  • Substitutional variants typically exchange one amino acid for another at one or more sites within the protein and may be designed to modulate one or more properties of the polypeptide, such as stability against proteolytic cleavage. Substitutions preferably are conservative, that is, one amino acid is replaced with another of similar shape and charge.
  • Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine or glutamine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.
  • Insertional variants include fusion proteins such as those used to allow rapid purification of the polypeptide and also may include hybrid proteins containing sequences from other homologous proteins and polypeptides.
  • an insertional variant may include portions of the amino acid sequence of the polypeptide from one species, together with portions of the homologous polypeptide from another species.
  • Other insertional variants may include those in which additional amino acids are introduced within the coding sequence of the polypeptide. These typically are smaller insertions than the fusion proteins described above and are introduced, for example, to disrupt a protease cleavage site.
  • major antigenic determinants of the polypeptide are identified by an empirical approach in which portions of the gene encoding the polypeptide are expressed in a recombinant host, and the resulting proteins tested for their ability to elicit an immune response.
  • PCR may be used to prepare a range of peptides lacking successively longer fragments of the C-terminus of the protein. The immunoprotective activity of each of these peptides then identifies those fragments or domains of the polypeptide which are essential for this activity. Further studies in which only a small number of amino acids are removed at each iteration then enables the location of the antigenic determinants of the polypeptide.
  • peptide mimetics are peptide-containing molecules which mimic elements of protein secondary structure. See, for example, Johnson et al, "Peptide Turn Mimetics” in BIOTECHNOLOGY AND PHARMACY, Pezzuto et al, Eds., Chapman and Hall, New York (1993).
  • the underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions, such as those of antibody and antigen.
  • a peptide mimetic is expected to permit molecular interactions similar to the natural molecule.
  • peptide mimetic concept has thus far focused on mimetics of ⁇ -turns within proteins, which are known to be highly antigenic.
  • ⁇ -turn structure within an polypeptide may be predicted by computer-based algorithms as discussed above. Once the component amino acids of the turn are determined, peptide mimetics may be constructed to achieve a similar spatial orientation of the essential elements of the amino acid side chains.
  • T03013, X03558, M28130, Y00787, SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:29 may be expressed as encoded peptides or proteins.
  • the engineering of DNA segment(s) for expression in a prokaryotic or eukaryotic system may be performed by techniques generally known in the art of recombinant expression. It is believed that virtually any expression system may be employed in the expression of the claimed isolated nucleic acids.
  • Both cDNA and genomic sequences are suitable for eukaryotic expression, as the host cell generally processes the genomic transcripts to yield functional mRNA for translation into protein.
  • genomic transcripts to yield functional mRNA for translation into protein.
  • Computer programs are available to aid in the selection of regions which have potential immunologic significance. Software capable of carrying out this analysis is readily available commercially, for example MacVector (IBI, New Haven, CT).
  • the software typically uses conventional algorithms such as the Kyte/Doolittle or Hopp/Woods methods for locating hydrophilic sequences which are characteristically found on the surface of proteins and are therefore likely to act as antigenic determinants.
  • a cDNA version of the gene It may be more convenient to employ as the recombinant gene a cDNA version of the gene. It is believed that the use of a cDNA version provides advantages in that the size of the gene is generally much smaller and more readily employed to transfect the targeted cell than a genomic gene, which is typically up to an order of magnitude larger than the cDNA gene. However, the possibility of employing a genomic version of a particular gene or fragments thereof is specifically contemplated.
  • engineered and recombinant cells are intended to refer to a cell into which an exogenous DNA segment or gene, such as a cDNA or gene has been introduced.
  • engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced exogenous DNA segment or gene.
  • Engineered cells are thus cells having a gene or genes introduced through the hand of man.
  • Recombinant cells include those having an introduced cDNA or genomic gene, and also include genes positioned adjacent to a promoter not naturally associated with the particular introduced gene.
  • an expression vector that comprises one of the claimed isolated nucleic acids under the control of, or operatively linked to, one or more promoters.
  • a coding sequence "under the control of a promoter, or to "operatively link” to a promoter, one positions the 5' end of the transcription initiation site of the transcriptional reading frame generally between about 1 and about 50 nucleotides “downstream” of (i.e., 3' of) the chosen promoter.
  • the "upstream” promoter stimulates transcription of the DNA and promotes expression of the encoded recombinant protein. This is the meaning of "recombinant expression” in this context.
  • Many conventional techniques are available to construct expression vectors containing the appropriate nucleic acids and transcriptional/translational control sequences in order to achieve protein or peptide expression in a variety of host-expression systems.
  • Cell types available for expression include, but are not limited to, bacteria, such as E.
  • prokaryotic hosts are E. coli strain RR1, E. coli LE392, E. coli ,
  • E. coli X 1776 ATCC No. 31557
  • E. coli W3110 F-, lambda-, prototrophic, ATCC No. 273325
  • bacilli such as Bacillus subtilis
  • enterobacteriaceae such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas species.
  • plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts.
  • the vector ordinarily carries a replication site, as well as marking sequences which are capable of providing phenotypic selection in transformed cells.
  • E. coli is often transformed using pBR322, a plasmid derived from an E. coli species.
  • pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells.
  • the pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters which may be used by the microbial organism for expression of its own proteins.
  • phage vectors containing replicon and control sequences that are compatible with the host microorganism may be used as transforming vectors in connection with these hosts.
  • the phage lambda GEM -11 may be utilized in making a recombinant phage vector which may be used to transform host cells, such as E. coli LE392.
  • Further useful vectors include pIN vectors (Inouye et al, 1985); and pGEX vectors, for use in generating glutathione S-transferase (GST) soluble fusion proteins for later purification and separation or cleavage.
  • GST glutathione S-transferase
  • Other suitable fusion proteins are those with ⁇ -galactosidase, ubiquitin, or the like.
  • Promoters that are most commonly used in recombinant DNA construction include the ⁇ - lactamase (penicillinase), lactose and tryptophan (tip) promoter systems. While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling their ligation into plasmid vectors.
  • the plasmid YRp7 for example, is commonly used.
  • This plasmid already contains the t l gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example ATCC No. 44076 or PEP4-1.
  • the presence of the t l lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.
  • Suitable promoting sequences in yeast vectors include the promoters for 3- phosphoglyceratekinase or other glycolytic enzymes, such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
  • the termination sequences associated with these genes are also ligated into the expression vector 3' of the sequence desired to be expressed to provide polyadenylationof the mRNA and termination.
  • promoters which have the additional advantage of transcription controlled by growth conditions, include the promoter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and the aforementioned glyceraldehyde-3 -phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization.
  • cultures of cells derived from multicellular organisms may also be used as hosts.
  • any such cell culture is workable, whether from vertebrate or invertebrate culture.
  • mammalian cells these include insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus); and plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing one or more coding sequences.
  • Autographia californica nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes.
  • the virus grows in Spodoptera frugiperda cells.
  • the isolated nucleic acid coding sequences are cloned into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).
  • Successful insertion of the coding sequences results in the inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene).
  • recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed (e.g., U.S. Patent No. 4,215,051 (Smith)).
  • useful mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, W138, BHK, COS-7, 293, HepG2, 3T3, RIN and MDCK cell lines.
  • a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the encoded protein.
  • Expression vectors for use in mammalian cells ordinarily include an origin of replication, a promoter located in front of the gene to be expressed, along with any necessary ribosome binding sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.
  • the origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.
  • the promoters may be derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Further, it is also possible to utilize promoter or control sequences normally associated with the gene sequence of interest, provided such control sequences are compatible with the host cell systems.
  • a number of viral based expression systems may be utilized.
  • commonly used promoters are derived from polyoma, Adenovirus 2, and most frequently Simian Virus 40 (SV40).
  • the early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the Hind III site toward the Bgl I site located in the viral origin of replication.
  • the coding sequences may be ligated to an adenovirus transcription/ translation control complex, e.g., the late promoter and tripartite leader sequence.
  • This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region El or E3) results in a recombinant virus that is viable and capable of expressing proteins in infected hosts.
  • Specific initiation signals may also be required for efficient translation of the claimed isolated nucleic acid coding sequences. These signals include the ATG initiation codon and adjacent sequences. Exogenous translational control signals, including the ATG codon, may additionally need to be provided. This need is readily determinable and the necessary signals readily provided. It is well known that the initiation codon must be in-frame (or in-phase) with the reading frame of the desired coding sequence to help ensure translation of the entire insert. These exogenous translational control signals and initiation codons may be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements or transcription terminators (Bittner et al. , 1987).
  • polyadenylation site e.g., 5'-AATAAA-3'
  • the poly A addition site is placed about 30 to 2000 nucleotides
  • cell lines that stably express constructs encoding proteins may be engineered.
  • host cells may be transformed with vectors controlled by appropriate expression control elements (e.g., promoter or enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.
  • appropriate expression control elements e.g., promoter or enhancer sequences, transcription terminators, polyadenylation sites, etc.
  • engineered cells may be allowed to grow for 1-2 days in an enriched medium and then are switched to a selective media.
  • the selectable marker in the recombinant plasmid confers resistance to the transformant and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn may be cloned and expanded into cell lines.
  • a number of selection systems may be used, including, but not limited, to the herpes simplex virus thymidine kinase (Wigler et al, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska et al, 1962) and adenine phosphoribosyltransferase genes (Lowy et al, 1980), in tk-, hgprt- or aprt- cells, respectively.
  • antimetabolite resistance may be used as the basis of selection for dhfr, that confers resistance to methotrexate (Wigler et al, 1980; O ⁇ are et al, 1981); gpt, that confers resistance to mycophenolic acid (Mulligan et al, 1981); neo, that confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al, 1981); and hygro, that confers resistance to hygromycin. It is contemplated that the isolated nucleic acids of the disclosure may be "overexpressed", i.e.
  • overexpression may be assessed by a variety of methods, including radio-labeling and/or protein purification. However, simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or Western blotting, followed by quantitative analyses, such as densitometric scanning of the resultant gel or blot.
  • a specific increase in the level of the recombinant protein or peptide in comparison to the level in natural human cells is indicative of overexpression, as is a relative abundance of the specific protein in relation to the other proteins produced by the host cell and, e.g., visible on a gel.
  • purification and in particular embodiments, the substantial purification, of an encoded protein or peptide.
  • the term "purified protein or peptide " as used herein, is intended to refer to a composition, isolatable from other components, wherein the protein or peptide is purified to any degree relative to its naturally- obtainable state, i.e., in this case, relative to its purity within a cell extract.
  • a purified protein or peptide therefore also refers to a protein or peptide, free from the environment in which it may naturally occur.
  • purified refers to a protein or peptide composition which has been subjected to fractionation to remove various other components, and which composition substantially retains its expressed biological activity. Where the term “substantially purified” is used, this refers to a composition in which the protein or peptide forms the major component of the composition, such as constituting about 50% or more of the proteins in the composition.
  • Various methods for quantifying the degree of purification of the protein or peptide are known in the art. These include, for example, determining the specific activity of an active fraction, or assessing the number of polypeptides within a fraction by SDS/PAGE analysis.
  • a preferred method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity, assessed by a "-fold purification number".
  • the actual units used to represent the amount of activity is dependent upon the particular assay technique chosen to follow the purification and whether or not the expressed protein or peptide exhibits an enzymatic or other activity.
  • Partial purification may be accomplished by using fewer purification steps in combination, or by utilizing different forms of the same general purification scheme. For example, it is appreciated that a cation-exchange column chromatography performed utilizing an HPLC apparatus generally results in a greater -fold purification than the same technique utilizing a low pressure chromatography system. Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein.
  • Antibody Generation it is preferred to produce antibodies that bind with high specificity to the protein product(s) of an isolated nucleic acid of a sequence comprising Genebank Accession numbers D87451, T03013, X03558, M28130, Y00787, SEQ ID NOT, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:29.
  • Means for preparing and characterizing antibodies are well known in the art (See, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988).
  • a polyclonal antibody is prepared by immunizing an animal with an immunogenic composition and collecting antisera from that immunized animal.
  • a wide range of animal species may be used for the production of antisera, including rabbits, mice, rats, hamsters, guinea pigs or goats. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.
  • a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a carrier.
  • exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin may also be used as carriers.
  • KLH keyhole limpet hemocyanin
  • BSA bovine serum albumin
  • Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin may also be used as carriers.
  • Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimideester, carbodiimide and bis-biazotized benzidine.
  • the immunogenicity of a particular immunogen composition may be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants.
  • adjuvants include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.
  • the amount of immunogen composition used in the production of polyclonal antibodies varies with the nature of the immunogen as well as the animal used for immunization.
  • a variety of routes may be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal).
  • the production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster, injection may also be given. The process of boosting and titering is repeated until a suitable titer is achieved.
  • the immunized animal may be bled and the serum isolated and stored, and/or the animal may be used to generate monoclonal antibodies.
  • the animal For production of rabbit polyclonal antibodies, the animal may be bled through an ear vein or alternatively by cardiac puncture. The removed blood is allowed to coagulate and then centrifuged to separate serum components from whole cells and blood clots.
  • the serum may be used as is for various applications or else a particular antibody fraction may be purified by well-known methods, such as affinity chromatography using another antibody or a peptide bound to a solid matrix.
  • Monoclonal antibodies may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265, incorporated herein by reference.
  • this technique involves immunizing a suitable animal with a selected immunogen composition, e.g., a purified or partially purified expressed protein, polypeptide or peptide.
  • the immunizing composition is administered in a manner effective to stimulate antibody producing cells, as described above.
  • the methods for generating monoclonal antibodies generally begin along the same lines as those for preparing polyclonal antibodies.
  • Rodents such as mice and rats are preferred animals, however, the use of rabbit, sheep or frog cells is also possible.
  • the use of rats may provide certain advantages (Goding, 1986, pp. 60-61), but mice are preferred, with the BALB/c mouse being most preferred as this generally gives a higher percentage of stable fusions.
  • the animals are injected with antigen as described above.
  • the antigen may be coupled to carrier molecules such as keyhole limpet hemocyanin if necessary.
  • the antigen is typically mixed with adjuvant, such as Freund's complete or incomplete adjuvant.
  • adjuvant such as Freund's complete or incomplete adjuvant.
  • Booster injections with the same antigen typically occur at approximately two- week intervals.
  • somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the MAb generating protocol.
  • B cells B lymphocytes
  • These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible.
  • a panel of animals are immunized and the spleen of the animal with the highest antibody titer is removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe.
  • a spleen from an immunized mouse contains
  • the antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized.
  • Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render then incapable of growing in selective media which support the growth of only the desired fused cells (hybridomas).
  • Any one of a number of myeloma cells may be used, as are known in the art (Goding, pp.
  • the immunized animal is a mouse
  • IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions.
  • NS-1 myeloma cell line also termed P3-NS-1- Ag4-1
  • Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line.
  • Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes.
  • Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter et al. (1977).
  • PEG polyethylene glycol
  • the use of electrically induced fusion methods is also appropriate (Goding pp. 71-74, 1986). Fusion procedures usually produce viable hybrids at low frequencies, about 1 X 10 " to
  • the selective medium is generally one that contains an agent that blocks the de novo synthesis of nucleotides in the tissue culture media.
  • agents are aminopterin, methotrexate, and azaserine.
  • Aminopterin and methotrexate block de novo synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis.
  • the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium).
  • HAT medium Hypoxanthine and thymidine as a source of nucleotides
  • azaserine the media is supplemented with hypoxanthine.
  • the preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells may operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that may survive in the selective media are those hybrids formed from myeloma
  • This culturing provides a population of hybridomas from which specific hybridomas are selected.
  • selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity.
  • the assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.
  • the selected hybridomas are then serially diluted and cloned into individual antibody-producing cell lines, which clones may then be propagated indefinitely to provide MAbs.
  • the cell lines may be exploited for MAb production in two basic ways.
  • a sample of the hybridoma may be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion.
  • the injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid.
  • the body fluids of the animal such as serum or ascites fluid, may then be tapped to provide MAbs in high concentration.
  • the individual cell lines may also be cultured in vitro, where the MAbs are naturally secreted into the culture medium from which they may be readily obtained in high concentrations.
  • MAbs produced by either means may be further purified as needed, using filtration, centrifugationand various chromatographic methods such as HPLC or affinity chromatography.
  • Monoclonal antibodies of the present disclosure may also be obtained by multiplying hybridoma cells in vivo.
  • Cell clones are injected into mammals which are histocompatible with the parent cells, e.g. , syngeneic mice, to cause growth of antibody-producing tumors.
  • the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane)prior to injection.
  • fragments of monoclonal antibodies may be obtained by methods which include digestion of monoclonal antibodies with enzymes such as pepsin or papain and/or cleavage of disulfide bonds by chemical reduction.
  • monoclonal antibody fragments encompassed by the present disclosure may be synthesized using an automated peptide synthesizer.
  • the monoclonal conjugates of the present disclosure are prepared by methods known in the art, e.g., by reacting a monoclonal antibody prepared as described above with, for instance, an enzyme in the presence of a coupling agent such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents or by reaction with an isothiocyanate. Conjugates with metal chelates are similarly produced. Other moieties to which antibodies may be conjugated include radionuclides such as 3 H, 125 I, 131 1 32 P, 35 S, 14 C, 51 Cr, 36 C1,
  • Radioactively labeled monoclonal antibodies of the present disclosure are produced according to well-known methods in the art. For instance, monoclonal antibodies may be iodinated by contact with sodium or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase.
  • Monoclonal antibodies according to the disclosure may be labeled with technetium by ligand exchange process, for example, by reducing pertechnate with stannous solution, chelating the reduced technetium onto a Sephadex column and applying the antibody to this column or by direct labeling techniques, e.g., by incubating pertechnate, a reducing agent such as SNC1 2 , a buffer solution such as sodium- potassium phthalate solution, and the antibody.
  • a reducing agent such as SNC1 2
  • a buffer solution such as sodium- potassium phthalate solution
  • monoclonal or polyclonal antibodies specific for proteins that are preferentially expressed in the peripheral blood of individuals with the disease state have utilities in several types of applications. These may include the production of diagnostic kits for use in detecting or diagnosing the disease state. It will be recognized that such uses are within the scope of the present invention.
  • the present disclosure concerns immunodetection methods for binding, purifying, removing, quantifying or otherwise generally detecting biological components.
  • the encoded proteins or peptides of the present disclosure may be employed to detect antibodies having reactivity therewith, or, alternatively, antibodies prepared in accordance with the present invention, may be employed to detect the encoded proteins or peptides.
  • the steps of various useful immunodetection methods have been described in the scientific literature, such as, e.g., Nakamura et al (1987).
  • the immunobinding methods include obtaining a sample suspected of containing a protein, peptide or antibody, and contacting the sample with an antibody or protein or peptide in accordance with the present invention, as the case may be, under conditions effective to allow the formation of immunocomplexes.
  • the immunobinding methods include methods for detecting or quantifying the amount of a reactive component in a sample, which methods require the detection or quantitation of any immune complexes formed during the binding process.
  • a sample suspected of containing a disease state-marker encoded protein, peptide or a corresponding antibody one obtains a sample suspected of containing a disease state-marker encoded protein, peptide or a corresponding antibody, and contacts the sample with an antibody or encoded protein or peptide, as the case may be, and then detects or quantifies the amount of immune complex formed under the specific conditions.
  • the biological sample analyzed would ordinarily consist of peripheral blood. However, it may be any sample that is suspected of containing a disease state- specific antigen, such as a lymph node tissue section or specimen, a homogenized tissue extract, an isolated cell, a cell membrane preparation, separated or purified forms of any of the above protein- containing compositions, or any other biological fluid that comes into contact with diseased tissues, including lymphatic fluid, urine and even seminal fluid.
  • a disease state-specific antigen such as a lymph node tissue section or specimen, a homogenized tissue extract, an isolated cell, a cell membrane preparation, separated or purified forms of any of the above protein- containing compositions, or any other biological fluid that comes into contact with diseased tissues, including lymphatic fluid, urine and even seminal fluid.
  • the encoded protein, peptide or corresponding antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined.
  • the first added component that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the encoded protein, peptide or corresponding antibody.
  • the second binding ligand may be linked to a detectable label.
  • the second binding ligand is itself often an antibody, which may thus be termed a "secondary" antibody.
  • the primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under conditions effective and for a period of time sufficient to allow the formation of secondary immune complexes.
  • the secondary immune complexes are then generally washed to remove any non-specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected.
  • Further methods include the detection of primary immune complexes by a two step approach.
  • a second binding ligand such as an antibody, that has binding affinity for the encoded protein, peptide or corresponding antibody is used to form secondary immune complexes, as described above.
  • the secondary immune complexes are contacted with a third binding ligand or antibody that has binding affinity for the second antibody, again under conditions effective and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes).
  • the third ligand or antibody is linked to a detectable label, allowing detection of the tertiary immune complexes thus formed. This system may provide for signal amplification if this is desired.
  • the immunodetection methods of the present disclosure have evident utility in the diagnosis of human disease states.
  • a biological or clinical sample suspected of containing either the encoded protein or peptide or corresponding antibody is used.
  • these embodiments also have applications to non-clinical samples, such as in the titering of antigen or antibody samples, in the selection of hybridomas, and the like.
  • the detection of an antigen encoded by a disease state marker nucleic acid, or an increase in the levels of such an antigen, in comparison to the levels in a corresponding biological sample from a normal subject is indicative of a patient with the disease state.
  • the basis for such diagnostic methods lies, in part, with the finding that the nucleic acid disease state markers identified in the present disclosure are overexpressed in peripheral blood samples from individuals with the disease state (see Examples 1 through 4 below). By extension, it may be inferred that at least some of these markers produce elevated levels of encoded proteins, that may also be used as disease state markers.
  • the antibodies of the present disclosure may also be used in conjunction with both fresh-frozen and formalin-fixed, paraffin-embedded tissue blocks prepared from study by immunohistochemistry (IHC) or fixed cells on microscope slides for immunocytochemistry.
  • IHC immunohistochemistry
  • the method of preparing tissue blocks from these particulate specimens has been successfully used in previous IHC studies of various prognostic factors and is well known to those of skill in the art (Brown et al, 1990; Abbondanzo et ⁇ /. , 1990; Allred et ⁇ /., 1990).
  • frozen-sections may be prepared by rehydrating 50 ng of frozen "pulverized” tissue at room temperature in phosphate buffered saline (PBS) in small plastic capsules; pelleting the particles by centrifugation; resuspending them in a viscous embedding medium (OCT); inverting the capsule and pelleting again by centrifugation; snap-freezing in -70°C isopentane; cutting the plastic capsule and removing the frozen cylinder of tissue; securing the tissue cylinder on a cryostat microtome chuck; and cutting 25-50 serial sections containing an average of about 500 intact cells.
  • PBS phosphate buffered saline
  • OCT viscous embedding medium
  • Permanent-sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube; pelleting; resuspending in 10% formalin for 4 hours fixation; washing/pelleting; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue/agar block from the tube; infiltrating and embedding the block in paraffin; and cutting up to 50 serial permanent sections.
  • Expressed proteins may also be detected by flow cytometry as described in Fujishima et al, 1996.
  • the cells are fixed and then incubated with a monoclonal antibody against the expressed protein to be detected.
  • the bound antibodies are then contacted with labeled anti-IgG for example for detection.
  • a typical label is FITC.
  • the fluorescent intensity may then be measured by flow cytometer such as Ortho Cytron, Ortho diagnostics, or FACScan; Becton Dickinson.
  • FACS permits the separation of sub-populations of cells initially on the basis of their light scatter properties as they pass through a laser beam.
  • the forward light scatter (FALS) is related to cell size and the right angle light scatter to cell density, cell contour and nucleo-cytoplasmic ratio. Since cells are tagged with fluorescent labeled antibody they can then be further characterized by fluorescence intensity and positive and negative windows set on the FACS to collect bright fluorescence and low fluorescence cells. Cells are sorted at a flow rate of about 3000 cells per second and collected in positive and negative cells.
  • the encoded proteins or peptides of the disclosure have utility as immunogens, e.g., in connection with vaccine development, in immunohistochemistry and in ELISA assays.
  • One evident utility of the encoded antigens and corresponding antibodies is in immunoassays for the detection of disease state marker proteins, as needed in diagnosis and prognostic monitoring.
  • Immunoassays in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful. However, it is readily appreciated that detection is not limited to such techniques, and Western blotting, dot blotting, FACS analyses, and the like may also be used.
  • antibodies binding to the encoded proteins of the disclosure are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the disease state marker antigen, such as a clinical sample, is added to the wells. After binding and washing to remove non- specifically bound immunecomplexes, the bound antigen may be detected. Detection is generally achieved by the addition of a second antibody specific for the target protein, that is linked to a detectable label. This type of ELISA is a simple "sandwich ELISA". Detection may also be achieved by the addition of a second antibody, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label.
  • the samples suspected of containing the disease state marker antigen are immobilized onto the well surface and then contacted with the antibodies of the invention. After binding and washing to remove non-specifically bound immunecomplexes, the bound antigen is detected. Where the initial antibodies are linked to a detectable label, the immunecomplexes may be detected directly. Again, the immunecomplexes may be detected using a second antibody that has binding affinity for the first antibody, with the second antibody being linked to a detectable label.
  • Another ELISA in which the proteins or peptides are immobilized involves the use of antibody competition in the detection.
  • labeled antibodies are added to the wells, allowed to bind to the disease state marker protein, and detected by means of their label.
  • the amount of marker antigen in an unknown sample is then determined by mixing the sample with the labeled antibodies before or during incubation with coated wells.
  • the presence of marker antigen in the sample acts to reduce the amount of antibody available for binding to the well and thus reduces the ultimate signal. This is appropriate for detecting antibodies in an unknown sample, where the unlabeled antibodies bind to the antigen-coated wells and reduces the amount of antigen available to bind the labeled antibodies.
  • ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immunecomplexes. These are described as follows: In coating a plate with either antigen or antibody, it is typical to incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period of hours. The wells of the plate are then washed to remove incompletely adsorbed material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test antisera. These include bovine serum albumin (BSA), casein and solutions of milk powder.
  • BSA bovine serum albumin
  • the coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.
  • a secondary or tertiary detection means rather than a direct procedure.
  • the immobilizing surface is contacted with the control and/or clinical or biological sample to be tested under conditions effective to allow immunecomplex (antigen/antibody) formation. Detection of the immunecomplex then requires a labeled secondary binding ligand or antibody, or a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or third binding ligand.
  • Under conditions effective to allow immunecomplex (antigen/antibody) formation means that the conditions preferably include diluting the antigens and antibodies with solutions such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween. These added agents also tend to assist in the reduction of nonspecific background.
  • the "suitable” conditions also mean that the incubation is at a temperature and for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours, at temperatures preferably on the order of 25° to 27°C, or may be overnight at about 4°C or so.
  • the contacted surface is washed so as to remove non-complexed material.
  • a preferred washing procedure includes washing with a solution such as PBS/Tween, or borate buffer. Following the formation of specific immunecomplexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immunecomplexes may be determined.
  • the second or third antibody has an associated label to allow detection.
  • this is an enzyme that generates color development upon incubating with an appropriate chromogenic substrate.
  • a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immunecomplex formation (e.g., incubation for 2 hours at room temperature in a PBS -containing solution such as PBS-Tween).
  • the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azido-di-(3-ethyl)-benzthiazoline-6-sulfonicacid [ABTS] and
  • a chromogenic substrate such as urea and bromocresol purple or 2,2'-azido-di-(3-ethyl)-benzthiazoline-6-sulfonicacid [ABTS]
  • Quantitation is then achieved by measuring the degree of color generation, e.g., using a spectrophotometer.
  • the antibodies of this disclosure are used to quantify and localize the expression of the encoded marker proteins.
  • the antibody for example, may be labeled by any one of a variety of methods and used to visualize the localized concentration of the cells producing the encoded protein.
  • a radionuclide may be bound to an antibody either directly or indirectly by using an intermediary functional group.
  • Intermediary functional groups which are often used to bind radioisotopes which exist as metallic ions to antibody are diethylenetriaminepentaacetic acid
  • DTP A ethyl ene diaminetetraceticacid
  • EDTA ethyl ene diaminetetraceticacid
  • ⁇ t,hi.s d,i.sc,losure are 9171- T ⁇ c, l 3 ⁇ I, 131 ⁇ I lll ⁇ In, 97r R>u, 67 C,-,u, 67 Ga, 12 5 ⁇ I, 68 ⁇ Ga, 72 A A s, 89 Z ⁇ r, and, 201.
  • T-TMl T-TMl.
  • the monoclonal antibody or fragment thereof may be labeled by any of several techniques known to the art.
  • the methods of the present disclosure may also use paramagnetic isotopes for purposes of in vivo detection. Elements particularly useful in
  • Magnetic Resonance Imaging include 157 Gd, 55 Mn, 162 Dy, 52 Cr, and 56 Fe.
  • Administration of the labeled antibody may be local or systemic and accomplished intravenously, intraarterially, via the spinal fluid or the like. Administration may also be intradermal or intracavitary, depending upon the body site under examination. After a sufficient time has lapsed for the monoclonal antibody or fragment thereof to bind with the diseased tissue, for example 30 minutes to 48 hours, the area of the subject under investigation is examined by routine imaging techniques such as MRI, SPECT, planar scintillation imaging and emerging imaging techniques, as well. The exact protocol necessarily varies depending upon factors specific to the patient, as noted above, and depending upon the body site under examination, method of administration and type of label used. The determination of specific procedures is routine in the art.
  • the distribution of the bound radioactive isotope and its increase or decrease with time is then monitored and recorded. By comparing the results with data obtained from studies of clinically normal individuals, the presence and extent of the diseased tissue may be determined.
  • the instant disclosure addresses detection of disease state cells by their effect on gene expression in immune system lymphocytes.
  • immune response may be localized.
  • the response may be limited to lymph nodes immediately surrounding a metastasizing tumor or other localized form of a disease state.
  • Localization of differentially expressed disease state markers may be of utility for separating disease states of widespread distribution from those of limited distribution within the patient. Such a detection means is therefore of significance in the management and care of patients with the disease state. It will be recognized that this utility is included within the scope of the present disclosure.
  • kits for use with the immunodetection methods described above.
  • the encoded proteins or peptides may be employed to detect antibodies and the corresponding antibodies may be employed to detect encoded proteins or peptides, either or both of such components may be provided in the kit.
  • the immunodetection kits thus comprise, in suitable container means, an encoded protein or peptide, or a first antibody that binds to an encoded protein or peptide, and an immunodetectionreagent.
  • the encoded protein or peptide, or the first antibody that binds to the encoded protein or peptide may be bound to a solid support, such as a column matrix or well of a microtiterplate.
  • the immunodetection reagents of the kit may take any one of a variety of forms, including those detectable labels that are associated with or linked to the given antibody or antigen, and detectable labels that are associated with or attached to a secondary binding ligand.
  • Exemplary secondary ligands are those secondary antibodies that have binding affinity for the first antibody or antigen, and secondary antibodies that have binding affinity for a human antibody.
  • suitable immunodetection reagents for use in the present kits include the two- component reagent that comprises a secondary antibody that has binding affinity for the first antibody or antigen, along with a third antibody that has binding affinity for the second antibody, the third antibody being linked to a detectable label.
  • kits may further comprise a suitably aliquoted composition of the encoded protein or polypeptide antigen, whether labeled or unlabeled, as may be used to prepare a standard curve for a detection assay.
  • kits may contain antibody-label conjugates either in fully conjugated form, in the form of intermediates, or as separate moieties to be conjugated by the user of the kit.
  • the components of the kits may be packaged either in aqueous media or in lyophilized form.
  • the container means of the kits generally includes at least one vial, test tube, flask, bottle, syringe or other container means, into which the antibody or antigen may be placed, and preferably, suitably aliquoted. Where a second or third binding ligand or additional component is provided, the kit also generally contains a second, third or other additional container into which this ligand or component may be placed.
  • the kits of the present disclosure also typically include a means for containing the antibody, antigen, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.
  • One embodiment of the instant disclosure comprises a method for identification of a disease state in a biological sample by amplifying and detecting nucleic acids corresponding to disease state markers.
  • the biological sample may be any tissue or fluid in which lymphocyte cells might be present.
  • Various embodiments include bone marrow aspirate, bone marrow biopsy, lymph node aspirate, lymph node biopsy, spleen tissue, fine needle aspirate, skin biopsy or organ tissue biopsy.
  • Other embodiments include samples of body fluid such as peripheral blood, lymph fluid, ascites, serous fluid, pleural effusion, sputum, cerebrospinal fluid, lacrimal fluid, stool or urine.
  • Nucleic acid used as a template for amplification is isolated from cells contained in the biological sample, according to conventional methodologies. (Sambrook et al. , 1989)
  • the nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to convert the RNA to a complementary cDNA.
  • the RNA is whole cell RNA and is used directly as the template for amplification.
  • Pairs of primers that selectively hybridize to nucleic acids corresponding to disease state- specific markers are contacted with the isolated nucleic acid under conditions that permit selective hybridization. Once hybridized, the nucleic acid:primer complex is contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles,” are conducted until a sufficient amount of amplification product is produced.
  • the amplification product is detected.
  • the detection may be performed by visual means.
  • the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of incorporated radiolabel or fluorescent label or even via a system using electrical or thermal impulse signals (Affymax technology; Bellus, 1994).
  • primer as defined herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process.
  • primers are oligonucleotides from ten to twenty base pairs in length, but longer sequences may be employed.
  • Primers may be provided in double-stranded or single-stranded form, although the single-stranded form is preferred.
  • PCR polymerase chain reaction
  • the primers bind to the marker and the polymerase causes the primers to be extended along the marker sequence by adding on nucleotides.
  • the extended primers dissociate from the marker to form reaction products, excess primers bind to the marker and to the reaction products and the process is repeated.
  • a reverse transcriptase PCR amplification procedure may be performed in order to quantify the amount of mRNA amplified.
  • Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook et al, 1989.
  • Alternative methods for reverse transcription utilize thermostable DNA polymerases. These methods are described in WO 90/07641 filed December 21, 1990. Polymerase chain reaction methodologies are well known in the art.
  • RNA species can be quantitated by means that do not necessarily require amplification by PCR.
  • These means may include other amplification techniques, for example, isothermic amplification techniques such as the one developed by Gen-Probe (San Diego, CA), and the ligase chain reaction ("LCR"), disclosed in EPA No. 320 308, incorporated herein by reference in its entirely.
  • LCR ligase chain reaction
  • two complementary probe pairs are prepared, and in the presence of the target sequence, each pair binds to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs link to form a single unit.
  • Qbeta Replicase described in PCT Application No. PCT/US 87/00880, may also be used as still another amplification method in the present invention.
  • a replicative sequence of RNA which has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase.
  • the polymerase copies the replicative sequence which may then be detected.
  • An isothermal amplification method in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleoside 5'-[alpha-thio]- triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention. Walker et al, Proc. Natl Acad. Sci. USA 89:392-396 (1992), incorporated herein by reference in its entirety.
  • Strand Displacement Amplification is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, i.e., nick translation.
  • a similar method called Repair Chain Reaction (RCR)
  • RCR Repair Chain Reaction
  • SDA Strand Displacement Amplification
  • RCR Repair Chain Reaction
  • Target specific sequences may also be detected using a cyclic probe reaction (CPR).
  • CPR a probe having 3' and 5' sequences of non-specific DNA and a middle sequence of specific RNA is hybridized to DNA which is present in a sample.
  • the reaction is treated with RNase H, and the products of the probe identified as distinctive products which are released after digestion.
  • the original template is annealed to another cycling probe and the reaction is repeated.
  • modified primers are used in a PCR like, template and enzyme dependent synthesis.
  • the primers may be modified by labeling with a capture moiety (e.g. , biotin) and/or a detector moiety (e.g. , enzyme).
  • a capture moiety e.g. , biotin
  • a detector moiety e.g. , enzyme
  • an excess of labeled probes are added to a sample.
  • the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labeled probe signals the presence of the target sequence.
  • nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR. Kwoh et al, Proc. Nat'l Acad. Sci. USA 86:1173 (1989); Gingeras et al, PCT Application WO 88/10315, incorporated herein by reference in their entirety.
  • TAS transcription-based amplification systems
  • NASBA nucleic acid sequence based amplification
  • 3SR 3SR.
  • Kwoh et al Proc. Nat'l Acad. Sci. USA 86:1173 (1989); Gingeras et al, PCT Application WO 88/10315, incorporated herein by reference in their entirety.
  • the nucleic acids may be prepared for amplification by conventional phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of
  • RNA hybrids are digested with RNase H while double stranded DNA molecules are heat denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target specific primer, followed by polymerization. The double-stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNA's are reverse transcribed into double stranded DNA, and transcribed once against with a polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate target specific sequences.
  • a polymerase such as T7 or SP6
  • ssRNA single-stranded RNA
  • dsDNA double-stranded DNA
  • the ssRNA is a first template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependentDNA polymerase).
  • RNA-dependentDNA polymerase reverse transcriptase
  • the RNA is then removed from the resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in duplex with either DNA or RNA).
  • RNase H ribonuclease H
  • the resultant ssDNA is a second template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by
  • RNA polymerase T7 RNA polymerase 5' to its homology to the template.
  • This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of E. coli DNA polymerase I), resulting in a double-stranded DNA (“dsDNA”) molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence.
  • dsDNA double-stranded DNA
  • This promoter sequence may be used by the appropriate RNA polymerase to make many RNA copies of the
  • the starting sequence may be chosen to be in the form of either DNA or RNA.
  • Miller et al, PCT Application WO 89/06700 (incorporated herein by reference in its entirety) disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic, i.e., new templates are not produced from the resultant RNA transcripts. Other amplification methods include "race” and "one-sided PCR.” Frohman, M.A., In: PCR PROTOCOLS: A GUIDE TO METHODS AND
  • nuclease protection assay An example of a technique that does not require nucleic acid amplification, that can also be used to quantify RNA in some applications is a nuclease protection assay.
  • nuclease protection assays There are many different versions of nuclease protection assays known to those practiced in the art. The characteristic that all versions of nuclease protection assays share in common is that they involve hybridization of an antisense nucleic acid with the RNA to be quantified. The resulting hybrid double stranded molecule is then digested with a nuclease that digests single stranded nucleic acids more efficiently than double stranded molecules. The amount of antisense nucleic acid that survives digestion is a measure of the amount of the target RNA species to be quantified.
  • An example of a nuclease protection assay that is commercially available is the RNase protection assay manufactured by
  • amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using conventional methods. See Sambrook et al, 1989.
  • chromatographic techniques may be employed to effect separation.
  • chromatography There are many kinds of chromatography which may be used in the present invention: adsorption, partition, ion-exchange and molecular sieve, HPLC, and many specialized techniques for using them including column, paper, thin-layer and gas chromatography (Freifelder, 1982).
  • Another example of a separation methodology is done by covalently labeling the oligonucleotide primers used in a PCR reaction with various types of small molecule ligands.
  • a different ligand is present on each oligonucleotide.
  • a molecule, perhaps an antibody or avidin if the ligand is biotin, that specifically binds to one of the ligands is used to coat the surface of a plate such as a 96 well ELISA plate.
  • the PCR products are bound with specificity to the surface.
  • a solution containing a second molecule that binds to the first ligand is added.
  • This second molecule is linked to some kind of reporter system.
  • the second molecule only binds to the plate if a PCR product has been produced whereby both oligonucleotide primers are incorporated into the final PCR products.
  • the amount of the PCR product is then detected and quantified in a commercial plate reader much as ELISA reactions are detected and quantified.
  • An ELISA-like system such as the one described here has been developed by the Raggio Italgene company under the C-Track trade name.
  • Amplification products must be visualized in order to confirm amplification of the marker sequences.
  • One typical visualization method involves staining of a gel with ethidium bromide and visualization under UV light.
  • the amplification products may then be exposed to x-ray film or visualized under the appropriate stimulating spectra, following separation.
  • visualization is achieved indirectly.
  • a labeled, nucleic acid probe is brought into contact with the amplified marker sequence.
  • the probe preferably is conjugated to a chromophore but may be radiolabeled.
  • the probe is conjugated to a binding partner, such as an antibody or biotin, where the other member of the binding pair carries a detectable moiety.
  • a binding partner such as an antibody or biotin
  • detection is by Southern blotting and hybridization with a labeled probe.
  • the techniques involved in Southern blotting are well known to those of skill in the art and may be found in many standard books on molecular protocols. See Sambrook et al, 1989. Briefly, amplification products are separated by gel electrophoresis. The gel is then contacted with a membrane, such as nitrocellulose, permitting transfer of the nucleic acid and non-covalent binding.
  • the membrane is incubated with a chromophore-conjugatedprobe that is capable of hybridizing with a target amplification product. Detection is by exposure of the membrane to x-ray film or ion-emitting detection devices.
  • kits This generally comprises preselected primers for specific markers. Also included may be enzymes suitable for amplifying nucleic acids including various polymerases (RT, Taq, etc.), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification.
  • enzymes suitable for amplifying nucleic acids including various polymerases (RT, Taq, etc.), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification.
  • kits generally comprise, in suitable means, distinct containers for each individual reagent and enzyme as well as for each marker primer pair.
  • Preferred pairs of primers for amplifying nucleic acids are selected to amplify the sequences specified in Genebank Accession numbers D87451, T03013, X03558, M28130, Y00787, SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:
  • kits comprise hybridization probes specific for disease state markers, chosen from a group including nucleic acids corresponding to the sequences specified in Genebank Accession numbers D87451, T03013, X03558, M28130, Y00787, SEQ ID NO:l, SEQ
  • kits generally comprise, in suitable means, distinct containers for each individual reagent and enzyme as well as for each marker hybridization probe.
  • RNA fingerprinting is a means by which RNAs isolated from many different tissues, cell types or treatment groups may be sampled simultaneously to identify RNAs whose relative abundances vary. Two forms of this technology were developed simultaneously and reported in 1992 as RNA fingerprinting by differential display (Liang and Pardee, 1992; Welsh et al, 1992). (See also Liang and Pardee, U.S. Patent 5,262,311, incorporated herein by reference in its entirety.)
  • RNA fingerprinting by PCR are theoretically similar but differ in their primer design and application.
  • the most striking difference between differential display and other methods of RNA fingerprinting is that differential display utilizes anchoring primers that hybridize to the poly A tails of mRNAs.
  • the PCR products amplified in differential display are biased towards the 3' untranslated regions of mRNAs.
  • Total cell RNA is primed for first strand reverse transcription with an anchoring primer composed of oligo dT.
  • the oligo dT primer is extended using a reverse transcriptase, for example,
  • MMLV Moloney Murine Leukemia Virus reverse transcriptase
  • RNA fingerprinting technology has been demonstrated as being effective in identifying genes that are differentially expressed in cancer cells (Liang et al, 1992; Wong et al, 1993; Sager et al, 1993; Mok et ⁇ /., 1994; Watsonet ⁇ /., 1994; Chen et al, 1995; An et al, 1995).
  • the present disclosure utilizes the RNA fingerprinting technique or other techniques described herein to identify genes that are differentially expressed in peripheral blood cells in human disease states.
  • PCR may be used to determine the relative concentrations of specific mRNA species in a series of total cell RNAs isolated from peripheral blood of normal individuals and individuals with a disease state. By determining that the concentration of a specific mRNA species varies, it is shown that the gene encoding the specific mRNA species is differentially expressed. This technique may be used to confirm that mRNA transcripts shown to be differentially regulated by RNA fingerprinting are differentially expressed in disease state progression.
  • the number of molecules of the amplified target DNA increase by a factor approaching two with every cycle of the reaction until some reagent becomes limiting. Thereafter, the rate of amplification becomes increasingly diminished until there is not an increase in the amplified target between cycles.
  • a curved line of characteristic shape is formed by connecting the plotted points. Beginning with the first cycle, the slope of the line is positive and constant. This is said to be the linear portion of the curve. After some reagent becomes limiting, the slope of the line begins to decrease and eventually becomes zero. At this point the concentration of the amplified target DNA becomes asymptotic to some fixed value. This is said to be the plateau portion of the curve.
  • the concentration of the target DNA in the linear portion of the PCR is directly proportional to the starting concentration of the target before the PCR was begun.
  • concentration of the PCR products of the target DNA in PCR reactions that have completed the same number of cycles and are in their linear ranges, it is possible to determine the relative concentrations of the specific target sequence in the original DNA mixture. If the DNA mixtures are cDNAs synthesized from RNAs isolated from different tissues or cells, the relative abundances of the specific mRNA from which the target sequence was derived may be determined for the respective tissues or cells. This direct proportionality between the concentration of the PCR products and the relative mRNA abundances is only true in the linear range portion of the PCR reaction.
  • the final concentration of the target DNA in the plateau portion of the curve is determined by the availability of reagents in the reaction mix and is independent of the original concentration of target DNA. Therefore, the first condition that must be met before the relative abundances of a mRNA species may be determined by RT-PCR for a collection of RNA populations is that the concentrations of the amplified PCR products must be sampled when the PCR reactions are in the linear portion of their curves.
  • the second condition that must be met for an RT-PCR study to successfully determine the relative abundances of a particular mRNA species is that relative concentrations of the amplifiable cDNAs must be normalized to some independent standard.
  • the goal of an RT-PCR study is to determine the abundance of a particular mRNA species relative to the average abundance of all mRNA species in the sample.
  • mRNAs for ⁇ -actin, asparagine synthetase and lipocortin II were used as external and internal standards to which the relative abundance of other mRNAs are compared.
  • Most protocols for competitive PCR utilize internal PCR standards that are approximately as abundant as the target. These strategies are effective if the products of the PCR amplifications are sampled during their linear phases.
  • the present disclosure enables the diagnosis and prognosis of human cancer by screening for marker nucleic acids.
  • markers have been proposed to be correlated with metastasis and malignancy. They may be classified generally as cytologic, protein or nucleic acid markers. Cytologic markers include such things as "nuclear roundedness" (Diamond et al. , 1982) and cell ploidy. Protein markers include prostate specific antigen (PSA) and CA125. Nucleic acid markers have included amplification of Her2/neu, point mutations in the p53 or ras genes, and changes in the sizes of triplet repeat segments of particular chromosomes.
  • a false positive result occurs when an individual without malignant cancer exhibits the presence of a "cancer marker" .
  • cancer marker For example, elevated serum PSA has been associated with prostate carcinoma. However, it also occurs in some individuals with non-malignant, benign hyperplasia of the prostate.
  • a false negative result occurs when an individual actually has cancer, but the test fails to show the presence of a specific marker. The incidence of false negatives varies for each marker, and frequently also by tissue type. For example, ras point mutations have been reported to range from a high of 95 percent in pancreatic cancer to a low of zero percent in some gynecologic cancers.
  • Ras point mutations may only be detected within the mutant cell, and are apparently not present in, for example, the serum or urine of individuals with r ⁇ s-activated carcinomas. This means that, in order to detect a malignant tumor, one must take a sample of the tumor itself, or its metastatic cells. Essentially one must first identify and sample a tumor before the presence of the cancer marker may be detected.
  • the ideal disease state marker would be one that is present in individuals with the disease state, and either missing or expressed at significantly lower levels in normal individuals.
  • the present disclosure addresses this need, in the case of metastatic prostate cancer for example, by identifying several new nucleic acid markers that are expressed at higher levels in individuals with metastatic prostate cancer than in normal individuals.
  • the results for markers UC302 (SEQ ID #3) and UC325 (SEQ ID #4) are quite promising in that these markers are apparently only overexpressed in the peripheral blood of individuals with metastatic tumors and are present at relatively low levels in normal individuals.
  • the present detection method avoids the problem of having to suspect a tumor is in place before it may be sampled.
  • the instant disclosure has utility as a general screening tool for asymptomatic individuals, as well as a means of differentially diagnosing those patients whose tumors have already metastasized. Depending upon the type of tumor involved, such individuals may be selected for systemic forms of anti-cancer therapy rather than surgical removal of localized tumor masses. Certain individuals with advanced forms of highly malignant metastatic tumors may be optimally treated by pain management alone. It is anticipated that in clinical applications, human tissue samples will be screened for the presence of the disease state markers identified herein. Such samples would normally consist of peripheral blood, but may also consist of needle biopsy cores or lymph node tissue.
  • nucleic acids would be extracted from these samples and amplified as described above. Some embodiments would utilize kits containing pre-selected primer pairs or hybridization probes. The amplified nucleic acids would be tested for the markers by, for example, gel electrophoresis and ethidium bromide staining, or Southern blotting, or a solid-phase detection means as described above. These methods are well known within the art. The levels of selected markers detected would be compared with statistically valid groups of individuals with metastatic, non-metastatic malignant, or benign tumors or normal individuals. The diagnosis and prognosis of the individual patient would be determined by comparison with such groups. Another embodiment of the present disclosure involves application of RT-PCR techniques to detect a disease state using probes and primers selected from sequences comprising Genebank
  • the disease state is detected in hematopoietic samples by amplification of disease state-specific nucleic acid sequences.
  • Samples taken from blood or lymph nodes are treated as described below to purify total cell RNA.
  • the isolated RNA is reverse transcribed using a reverse transcriptase and primers selected to bind under high stringency conditions to a nucleic acid sequence from a group comprising Genebank Accession numbers D87451, T03013, X03558,
  • the presence of amplification products corresponding to disease state-marker nucleic acids may be detected by several alternative means.
  • the amplification product may be detected by gel electrophoresis and ethidium bromide staining.
  • the amplification product may be detected by conventional Southern blotting techniques, using an hybridization probe selected to bind specifically to a disease state-marker nucleic acid sequence.
  • Probe hybridization may in turn be detected by a conventional labeling means, for example, by incorporation of [ P]-nucleotides followed by autoradiography.
  • the amplification products may alternatively be detected using a solid phase detection system such as those utilizing a disease state-marker specific hybridization probe and an appropriate labeling means, or even the ELIS A-like system known as C-trackTM as described above.
  • RNA fingerprinting (according to Liang and Pardee, 1992; Welsh et al, 1992; Liang and Pardee, 1993) was applied to nucleic acids isolated from the peripheral blood of individuals with metastatic prostate cancer, compared with normal individuals.
  • the redissolved nucleic acids were then digested with RNase-free DNase I (Boehringer Mannheim, Inc.) following the manufacturer's instructions, followed by organic extraction with phenol:chloroform:isoamylalcohol (25 :24: 1 ) and re-precipitation with ethanol.
  • RNase-free DNase I Boehringer Mannheim, Inc.
  • the DNase I treated RNA was then pelleted by centrifugation and redissolved in water. The purity and concentration of the RNA in solution was estimated by determining optical density at wave lengths of 260 nm and 280 nm (Sambrook et al. , 1989). The RNA was then examined by electrophoresis on a native TAE agarose gel (Sambrook et al. , 1989) to determine its integrity. The RNA was then divided into three aliquots. One aliquot was set aside for relative quantitative RT-
  • a second aliquot was used to fingerprint the RNA by converting the RNA to first strand cDNA using random hexamers and reverse transcriptase; fingerprinting the cDNA by PCR using arbitrarily chosen oligonucleotides, (10 nucleotides in length); displaying the resulting PCR amplified products on an agarose gel stained with ethidium bromide and cutting differentially appearing bands out of the gel. The excised bands were then cloned and sequenced.
  • RNA of the third aliquot was pooled to make a pool of blood RNA from normal individuals and a pool of RNA from the blood of patients with metastatic prostate cancer.
  • the pools were fingerprinted using the sequential pairwise method of arbitrarily primed PCR fingerprinting of RNA (McClelland et al., 1994, Nucleic Acids Research 22, 4419-4431, incorporated herein by reference) with several changes.
  • arbitrary oligonucleotides of 15 to 24 nucleotides were used with Taq polymerase, and one tenth of each first strand cDNA reaction in each arbitrarily primed PCR reaction.
  • One hundred and 200 ng were used in each first strand cDNA synthesis, respectively. Certain genes disclosed herein were discovered by the sequential pairwise method.
  • RNA fingerprinting studies performed more closely resembled the protocol of Welsh et al. (1992).
  • This approach used a variation of the above as modified by the use of agarose gels and non-isotopic detection of bands by ethidium bromide staining (An et al. ,
  • RNAse-free DNAse I GENERAL HCI
  • KCl KCl
  • MgCl 2 mM MgCl 2
  • RNAse inhibitor Boehringer Mannheim
  • RNA sample Two ⁇ g of each total cell RNA sample was reverse transcribed into cDNA using randomly selected hexamer primers and MMLV reverse transcriptase (GIBCO/BRL).
  • PCR was performed using one or two arbitrarily chosen oligonucleotide primers (10-12mers). PCR conditions were: 10 mM Tris-HCI (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 50 mM dNTPs, 0.2 mM of primer(s), 1 unit of Taq DNA polymerase (GIBCO/BRL) in a final volume of 20 ml.
  • the amplification parameters included 35 cycles of reaction with 30 sec denaturing at 94°C, 90 sec annealing at 40°C, and 60 sec extension at 72°C. A final extension at 72°C was performed for 15 min.
  • the resulting PCR products were resolved into a fingerprint by size separation by electrophoresis through 2% agarose gels in TBE buffer (Sambrook et al, 1989). The fingerprints were visualized by staining with ethidium bromide. No re-amplification was performed.
  • PCR products that might represent differentially expressed genes, were excised from the gel with a razor blade, purified from the agarose using the Geneclean kit (Bio 101, Inc.), eluted in water and cloned directly into plasmid vectors using the TA cloning strategy (Invitrogen, Inc., and Promega, Inc.). These products were not re-amplified after the initial PCR fingerprinting protocol. 3. Confirmation of Differential Expression by Relative Quantitative RT-PCR:
  • Protocols for RT-PCR a Reverse transcription
  • One to five ⁇ g of total cell RNA from each tissue sample was reverse transcribed into cDNA.
  • Reverse transcription was performed with 400 units of MMLV reverse transcriptase (GIBCO/BRL) in the presence of 50 mM Tris-HCI (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM
  • RT-PCR was utilized to examine mRNAs for differential expression.
  • the sequences of oligonucleotides used as primers to direct the amplification of the various cDNA fragments are presented in Table 3.
  • RNA concentrations of the original total cell RNAs were determined by measurement of OD 26028 o (Sambrook et al, 1989) and confirmed by examination of ribosomal RNAs on ethidium bromide stained agarose gels. It is required that all quantitative PCR reactions be normalized for equal amounts of amplifiable cDNA after the reverse transcription is completed. One solution to this is to terminate the reactions by driving the PCR reactions into plateau phase. This approach was utilized in some studies because it is quick and efficient. Lipocortin II was used as the internal standard or competitor. These PCRs were set up as follows:
  • Reagents 200 mM each dNTP, 200 nM each oligonucleotide primer, IX PCR buffer (Boehringer Mannheim including 1.5 mM MgCl 2 ), 3 ml diluted cDNA, and 2.5 units of Taq DNA polymerase/ 100 ml of reaction volume. Cycling parameters: 30 cycles of 94°C for 1 min; 55°C for 1 min; and 72°C for two min. Thermocyclerswere either the MJ research thermocycler or the Stratagene Robocycler.
  • the quantified data was then normalized for variations in the starting concentrations of amplifiable cDNA by comparing the quantified data from each study with that derived from a similar study which amplified a cDNA fragment copied from the ⁇ -actin mRNA. Quantified data that had been normalized to beta actin were converted into bar graph representations.
  • the corrected f/t PSA ratio was determined according to Marley et al, 1996.
  • Reference standards for free and total PSA assays were purchased from the Stanford University Prostate Center and consisted of an equimolar mixture of 90% PSA- -1-antichymotrypsin and 10% free-PSA (Stamey, 1995; Chen et al, 1995). All testing dilutions were performed with 1% bovine serum albumin (Fraction V; Sigma Chemical Co.) in 20 mM phosphate-buffered saline
  • the (TOSOH) total PSA assay reacted equally to the free and bound (PSA-ACT) forms of PSA.
  • the (lmmulite) free PSA assay system was unable to detect the bound fraction of PSA (PSA- ACT) below a concentration of 20 ng/ml.
  • Antibodies for detecting both total and free PSA were unable to detect PSA covalently linked to ⁇ -2 macroglobulin (PSA-MG or occult PSA).
  • ROC Receiver Operator Characteristics Curves analyses were derived by Logistic regression modeling using the STATATM software package (Stata Corporation, College Station, TX). Classification and Regression Tree (CART) analysis (CART vl.01, SYSTAT Inc., Evanston, IL), was used to determine the optimal cutoff for the serum assays as well as the logistic regression models (Breiman et al, 1984; Steinberg and Colla,
  • IL-8 Quantitation A commercial IL-8 immunoassay kit was purchased for use in this study (IL-8
  • Solid Phase Immunoassay Cat. #D8050, 96 well microtiter plate format, from R&D Systems, 614 McKinley PI. NE; Minneapolis, MN 55413). Solutions consisted of wash buffer, substrate solution (color reagents A&B), calibrator diluent RD6Z, assay diluent RDl-8, stop solution and IL-8 stock solution (2000 pg/ml). To prepare the IL-8 standards, 500 ⁇ l of calibrator diluent RD6Z was pipetted into each of a series of dilution tubes. A serial dilution of the IL-8 stock solution (2000 pg/ml) was prepared to yield standards of the following concentrations: 1000, 500, 250, 125, 62.5, 31.2, 15.6, 7.8 pg/ml.
  • the manufacturer's recommended protocol was used to assay IL-8 concentrations. All reagents and samples were first brought to room temperature. The assay mixture contained in each well; 100 ⁇ l of assay diluent RDl-8, 50 ⁇ l of sample (or appropriate standard) and 100 ⁇ l of
  • IL-8 conjugate The wells were covered with the provided adhesive strip and samples were incubated for 3 hours at room temperature. Each assay well was aspirated and washed with wash buffer for a total of six washes. After the final wash, the plate was inverted onto a paper towel to wick up excess moisture. Then 200 ⁇ l of substrate solution was added to each assay well and incubated for 30 min at room temperature. Fifty ⁇ l of stop solution was added to each assay well and mixed by gentle tapping. Optical density was measured within 30 min of addition of stop solution, using a Bio-Tek EL-808 microplate reader (96 well format) at 450 nm.
  • IL-8 Standard Curve and Coefficient of Variation The IL-8 standard curve consisted of eight concentrations: 1000, 500, 250, 125,
  • Relative Quantitative Reverse Transcriptase-PolymeraseChain Reaction - A method to evaluate novel genes (ESTs) as diagnostic biomarker s.
  • RT-PCR reverse transcription-polymerase chain reaction
  • the protocol described herein addresses each of these six barriers and has permitted the realization of the potential of RT-PCR for this application.
  • the present example is drawn to the identification and confirmation of differential expression in various physiological states in prostate tissue, the methods described herein may be applied to any type of tissue, and particularly to peripheral blood cells to provide a sensitive method of identifying differential expression.
  • the inventors have described the examination of candidate genes by this method that were partial cDNA fragments identified by RNA fingerprinting methodologies. This necessitated development of a relatively quantitative approach to independently confirm the differential expression of the mRNAs from which these partial cDNA fragments were derived.
  • the key objective of the described screening protocol is the assessment of changes in the relative abundances of mRNA.
  • the gene discovery program previously described is focused on analysis of human tissue and confirmation must be performed on the same biological material. Access to human tissue for isolation of RNA is limited. This limitation is especially problematic in Northern blots, the traditional means to determine differential gene expression. Northern blots typically consume roughly 20 ⁇ g of RNA per examined tissue per gene identified. This means that for the average size of tissue sample available, only 1 -5 Northern blots can be performed before all of the RNA from a tissue sample is completely consumed. Clearly Northern blots are seriously limited for primary confirmation of discovered genes and consume extremely valuable biological resources required for gene discovery and characterization.
  • RT-PCR reverse transcription
  • RT-PCR consumes relatively small quantities of RNA. With 20 ⁇ g of RNA per examined sample, the amount of RNA required to perform a single Northern blot experiment, 50-200 RT-PCR assays may be performed with up to four data points per assay. Another advantage is a high throughput, eight independent experiments which examine eight different mRNA species for differential expression may be performed simultaneously in a single
  • PCR machine with 96 wells. A single individual skilled in this technique may thereby examine and evaluate eight genes per day without significant time constraints. By comparison, even if RNA of sufficient quality and quantity were available to do this number of Northern blots, a similarly skilled individual performing Northern blots would be hard pressed to examine and evaluate eight genes per week. In addition to the lower throughput rate of Northern blots, eight Northern blots per week would require the consumption of about 400 ⁇ Ci of P per week. While not dangerous to use in the hands of a skilled individual, P is certainly inconvenient to use. RT- PCR avoids the use of radioactive materials.
  • RT-PCR is much less sensitive to differences in quality of the RNA being examined.
  • the human tissues described were removed from patients for treatment purposes and were only incidentally saved for further studies.
  • the RNA an extremely labile molecule, is expected to be at least partially degraded. Because the RNA is separated by size on a gel in the Northern blot assay, partially degraded RNA appears as a smear, rather than discrete bands.
  • RT-PCR amplifies only a section or domain of an RNA molecule, and as long as that portion is intact, the size or degradation state of the entire molecule is irrelevant.
  • RNAs that are identical except that they vary by degree of partial degradation will give much more variable signals in a Northern blot than they will in an RT-PCR.
  • samples are of variable quality, as is often the case in human studies, the relative sensitivities of the techniques to variation in sample quality is an important consideration.
  • total cell RNA is first converted into cDNA using reverse transcriptase primed with random hexamers.
  • This protocol results in a cDNA population in which each RNA has contributed according to its relative proportion in original total cell RNA. If two RNA species differ by ten fold in their original relative abundances in the total cell RNA, then the cDNA derived from these two RNAs will also differ by ten fold in their relative abundances in the resulting population of cDNA. This is a conservation of relative proportionality in the conversion of RNA to cDNA.
  • M the mass of the targeted cDNA molecules before the beginning of PCR
  • C the number of PCR cycle performed.
  • E is an efficiency of amplification factor. This factor is complex and varies between 1 and 2. The important consideration in this assay is that over most of a PCR amplification, E will be nearly constant and nearly equal to 2. In PCR reactions that are identical in every way except the cDNAs being used as templates are derived from different total cell RNAs, then E will have the same value in each reaction.
  • a cDNA target has an initial mass of M, in one PCR reaction and a mass of M 2 in another PCR reaction and if E has the same value in each reaction, then after C cycles of PCR there will be a mass of M](E ) of the amplified c target in the first reaction and a mass of M 2 (E ) of the amplified target in the second reaction.
  • both reverse transcription and PCR may be performed in such a way as to conserve proportionality, it is possible to compare the relative abundance of an mRNA species in two or more total cell RNA populations by first converting the RNA to cDNA and then amplifying a fragment of the cDNA derived from the specific mRNA by PCR.
  • the ratio of the amplified masses of the targeted cDNA is very close to or identical to the ratios of the mRNAs in the original total cell RNA populations.
  • RNA must be free of contaminants that might interfere with reverse transcription.
  • RT The efficiency of RT is variable. cDNAs, not RNA, must be normalized for equal concentrations of amplifiable cDNA. 5) Limited linear range requires multiple sampling points in any amplification curve.
  • the first three barriers to successful RT-PCR are all related to the quality of the RNA used in this assay.
  • the protocols described in this section address the first two barriers as described in the last section. These are the requirements that degradation of RNA must be minimized during RNA preparation and that genomic DNA must be eliminated from the RNA.
  • Two preferred methods for RNA isolation are the guanidinium thiocyanate method, which is well known in the art, and kits for RNA isolation manufactured by Qiagen, Inc.
  • RNA isolation methods are performed on the RNA isolated by either method (or any method) before the RNA is be used in RT-PCR.
  • the first of these four protocols is digestion of the RNAs with Dnasel to remove all genomic DNA that was co-isolated with the total cell RNA.
  • the RNA Prior to DNasel digestion, the RNA is in a particulate suspension in 70% ethanol. Approximately 50 ⁇ g of RNA (as determined by OD 26 o /280 ) is removed from the suspension and precipitated. This RNA is resuspended in DEPC treated sterile water. To this is added 10X DNasel buffer (200 mM Tris-HCI; pH 8.4, 20 mM
  • RNA MgCl 2 , 500 mM KCl
  • 10 units of RNase Inhibitor GEBCO-BRL Cat#l 5518-012
  • 20 units of DNasel GBCO-BRL # 18068-015
  • the volume is adjusted to 50 ⁇ l with additional DEPC treated water.
  • the reaction is incubated at 37°C for 30 minutes.
  • After DNasel digestion the RNAs are organic solvent-extracted with phenol and chloroform followed by ethanol precipitation. This represents the second ethanol precipitation of the isolated RNA.
  • Empirical observations suggest that this repeated precipitation improves RNA performance in the RT reaction to follow.
  • An aliquot of the RNA suspension in ethanol is removed and divided into thirds. A different procedure is performed on each one of the aliquot thirds. These three procedures are: (1). An OD 260 280 is obtained using a standard protocol and is used to estimate the amount of RNA present and its likely quality. (2). An aliquot is run out on an agarose gel, and the RNA is stained with ethidium bromide. Observation that both the 28S and 18S RNAs are visible as discreet bands and that there is little staining above the point at which the 28 S rRNA migrates indicate that the RNA is relatively intact.
  • RNA While it is not critical to assay performance that the examined RNAs be completely free of partial degradation, it is important to determine that the RNA is not so degraded as to significantly effect the appearance of the 28S rRNA. (3).
  • the total cell RNAs are run using a PCR-based test that confirms that the DNasel treatment actually digested the contaminating genomic DNA to completion. It is very important to confirm complete digestion of genomic DNA because genomic DNA may act as a template in PCR reactions resulting in false positive signals in the relative quantitative RT-PCR assay described below.
  • the assay for contaminating genomic DNA utilizes gene specific oligonucleotides that flank a 145 nucleotide long intron (intron #3) in the gene encoding Prostate Specific Antigen (PSA).
  • PSA Prostate Specific Antigen
  • the sequences of these oligonucleotides are:
  • IX GIBCO-BRL PCR reaction buffer [20 mM Tris-Cl (pH 8.4), 50 mM KCl] 1.5 mM MgCl 2
  • RNA 2.5 units of Taq polymerase per lOO ⁇ l of reaction volume. Using these conditions, PCR is performed with 35-40 cycles of: 94°C for 45 sec 55°-60°C for 45 sec 72°C for 1 :00 minute.
  • the protocols described in the above section permit isolation of total cellular RNA that overcomes two of the six barriers to successful RT-PCR, i.e. the RNA is acceptably intact and is free from contaminating genomic DNA.
  • Reverse transcriptases also called RNA dependent DNA polymerases, as applied in currently used molecular biology protocols, are known to be less processive than other commonly used nucleic acid polymerases. It has been observed that not only is the efficiency of conversion of RNA to cDNA relatively inefficient, there is also several fold variation in the efficiency of cDNA synthesis between reactions that use RNAs as templates that otherwise appear indistinguishable. The sources of this variation are not well characterized, but empirically, it has been observed that the efficiencies of some reverse transcription (RT) reactions may be improved by repeated organic extractions and ethanol precipitations. This implies that some of the variation in RT is due to contaminants in the RNA templates.
  • RT reverse transcription
  • the DNasel treatment described above may be aiding the efficiency of RT by subjecting the RNA to an additional cycle of extraction with phenol and chloroform and ethanol precipitation. Contamination of the template RNA with inhibitors of RT is an important barrier to successful
  • Reverse transcription reactions are performed using the SuperscriptTM Preamplification System for First Strand cDNA Synthesis kit which is manufactured by GIBCO-BRL LifeTechnologies (Gaithersburg, MD).
  • SuperscriptTM is a cloned form of M-MLV reverse transcriptase that has been deleted for its endogenous Rnase H activity in order to enhance its processivity.
  • the published protocols of the manufacturer are used for cDNA synthesis primed with random hexamers.
  • cDNA synthesis may also be primed with a mixture of random hexamers (or other small oligonucleotides of random sequence) and oligo dT.
  • oligo dT increases the efficiency of conversion of RNA to cDNA proximal to the polyA tail.
  • template either 5 or 10 micrograms of RNA is used (depending on availability).
  • the RT reaction is diluted with water to a final volume of 100 ⁇ l.
  • cDNA populations made from different RT reactions may be normalized to contain equal concentrations of amplifiable cDNA synthesized from mRNAs that are known not to vary between the physiological states being examined.
  • cDNAs made from total cell RNAs are normalized to contain equal concentrations of amplifiable b-actin cDNA.
  • oligonucleotides specific to ⁇ -actin are designed to cross introns, permitting the differentiation of cDNA and genomic DNA.
  • ⁇ -actin specific oligonucleotides have the sequences: 5' CGAGCTGCCTGACGGCCAGGTCATC 3', SEQ ID NO:8 and
  • PCR 5' GAAGCATTTGCGGTGGACGATGGAG 3'
  • SEQ ID NO:9 PCR is performed under standard conditions as described previously for either 19 or 20 cycles.
  • the resulting PCR product is 415 nucleotides in length.
  • the product is examined by PCR using agarose gel electrophoresis followed by staining with ethidium bromide.
  • the amplified cDNA fragment is then visualized by irradiation with ultra violet light using a transilluminator.
  • a white light image of the illuminated gel is captured by an IS-1000 Digital Imaging System manufactured by Alpha Innotech Corporation.
  • the captured image is analyzed using either version 2.0 or 2.01 of the software package supplied by the manufacturer to determine the relative amounts of amplified ⁇ -actin cDNA in each RT reaction.
  • water is added to the most concentrated cDNAs as determined by the assay described in the last paragraph.
  • PCR using 1 ⁇ l of the newly rediluted and adjusted cDNA is repeated using the ⁇ -actin oligonucleotides as primers. The number of cycles of PCR must be increased to 21 or 22 cycles in order to compensate for the decreased concentrations of the newly diluted cDNAs.
  • the cDNAs may be adjusted by dilution to contain roughly equal concentrations of amplifiable cDNA. Sometimes this process must be repeated to give acceptable final normalization.
  • a normalization statistic may be created that will permit more accurate comparisons of the relative abundances of RNAs examined in the normalized panel of cDNAs.
  • PCR may be performed using different gene specific oligonucleotides as primers to determine the relative abundances of other mRNAs as represented as cDNAs in the normalized panel of diluted RT reaction products.
  • the relative intensities of the bands is then adjusted and normalized to ⁇ -actin expression by multiplying the intensity quantities by the normalization statistics derived.
  • This part of the PCR where the efficiency of amplification is decreased is called the "plateau" phase of the amplification curve. When "E" ceases to behave as a constant and the PCR begins to move towards the plateau phase, the conservation of relative proportionality of amplified products during PCR is lost.
  • PCR products be quantified in the linear portion of the amplification curve. This is technically difficult because currently used means of DNA quantitation are only sensitive enough to quantify the PCR products when they are approaching concentrations at which the product strands begin to compete with the primers for annealing. This means that the PCR products may only be detected at the very end of the linear range of the amplification curve. Predicting in advance at what cycle number the PCR products should be quantified is technically difficult. Practically speaking, it is necessary to sample the PCR products at a variety of cycle numbers that are believed to span the optimum detection range in which the products are abundant enough to detect, but still in the linear range of the amplification curve. It is impractical to do this in a study that involves large numbers of samples because the number of different PCR reactions and/or number of different electrophoretic gels that must be run becomes prohibitively large.
  • a two tiered approach was designed to relatively quantify mRNA abundance levels using RT-PCR.
  • pools of cDNAs produced by combining equal amounts of normalized cDNA are examined to determine how mRNA abundances vary in the average individual with a particular physiological state. This reduces the number of compared samples to a very small number such as two to four.
  • two pools are examined. These are pools of normal individuals and those individuals with metastatic prostate cancer. Each pool may contain a large number of individuals. While this approach does not discriminate differences between individuals, it may easily discern broad patterns of differential expression.
  • the great advantage of examining pooled cDNAs is that it permits many duplicate PCR reactions to be simultaneously set up.
  • the individual duplicates may be harvested and examined at different cycle numbers of PCR.
  • four duplicate PCR reactions were set up. One duplicate was collected at 31, 34, 37, and 40 PCR cycles. Occasionally, PCR reactions were also collected at 28 cycles. Examining the PCRs at different cycle numbers yielded the following benefits. It is very likely that at least one of the RT-PCRs will be in the optimum portion of the amplification curves to reliably compare relative mRNA abundances. In addition, the optimum cycle number will be known, so that studies with much larger sample sizes are much more likely to succeed. This is the second tier of a two tiered approach that has been taken to relatively quantify mRNA abundance levels using RT-PCR.
  • RT-PCR with the pooled samples permits much more efficient application of RT-PCR to the samples derived from individuals.
  • tube to tube variability in PCR may be discounted and controlled because most studies yield multiple data points due to duplication.
  • the first step in this protocol is to normalize the pooled samples to contain equal amounts of amplifiable cDNA. This is done using oligonucleotides that direct the amplification of ⁇ -actin.
  • a PCR amplification of a cDNA fragment derived from the ⁇ -actin mRNA from pools of normal individuals and individuals with metastatic prostate cancer was performed. This study was set up as four identical PCR reactions. The products of these PCRs were collected and electrophoresed after 22, 25, 28 and 31 PCR cycles. Quantitation of these bands using the IS 1000 system showed that the PCRs were still in the linear ranges of their amplification curves at 22, 25 and 28 cycles but that they left linearity at 31 cycles.
  • the central question to be answered in analyzing this data is whether the PCRs have been examined in the linear portions of their amplification curves.
  • a test for this may be devised by determining if the proportionality of the PCR products has been conserved as PCR cycle number has increased. If the ratio between the two pools of a given PCR product remains constant with increasing cycle number, this is strong evidence that the PCRs were in the linear portions of their amplification curves when these observations were made. (This is better conservation of proportionality than is frequently observed. In some studies, data was excepted when the ratios were similar but not identical.) This conservation of proportionality was lost at 40 cycles. This indicates that these PCRs are nearing the plateau phases of their amplification curves.
  • the final major barrier to quantifying relative mRNA abundances with RT-PCR is tube to tube variability in PCR. This may result from many factors, including unequal heating and cooling in the thermocycler, imperfections in the PCR tubes and operator error. To control for this source of variation, the Cole-Parmer digital thermocouple Model # 8402-00 was used to calibrate the thermocyclers used in these studies. Only slight variations in temperature were observed.
  • the RT-PCR protocol examining pooled cDNAs is internally controlled for tube to tube variability that might arise from any source.
  • By examining the abundance of the PCR products at several different cycle numbers it may be determined that the mass of the expected PCR product is increasing appropriately with increasing PCR cycle number. Not only does this demonstrate that the PCRs are being examined in the linear phase of the PCR, where the data is most reliable, it demonstrates that each reaction with the same template is consistent with the data from the surrounding cycle numbers. If there was an unexplained source of variation, the expectation that PCR product mass would increase appropriately with increasing cycle number would not be met. This would indicate artifactual variation in results. Internal duplication and consistency of the data derived from different cycle numbers controls for system derived variation in tube to tube results.
  • the RT-PCR protocol using pooled cDNA templates overcomes the last two barriers to effective relative quantitative RT-PCR. These barriers are the need examine the PCR products while the reactions are in the linear portions of their amplification curves and the need to control tube to tube variation in PCR.
  • the described protocol examines PCR products at three to four different cycle numbers. This insures that the PCRs are quantitated in their linear ranges and, as discussed in the last paragraph, controls for possible tube to tube variation.
  • ⁇ -actin is an appropriate internal standard for mRNA quantitation.
  • ⁇ -actin has been used by many investigators to normalize mRNA levels. Others have argued that ⁇ -actin is itself differentially regulated and therefore unsuitable as an internal normalization standard.
  • differential regulation of ⁇ -actin is not a concern. More than fifty genes have been examined for differential expression using these protocols. Fewer than half were actually differentially expressed. The other half were regulated similarly to ⁇ -actin within the standard error of 13%. Either all of these genes are coordinately differentially regulated with ⁇ -actin, or none of them are differentially regulated.
  • ⁇ -actin has also been criticized by some as an internal standard in PCRs because of the large number of pseudogenes of ⁇ -actin that occur in mammalian genomes. This is not a consideration in the described assays because all of the RNAs used herein are demonstrated to be free of contaminating genomic DNA by a very sensitive PCR based assay. In addition, the cycle number of PCR needed to detect ⁇ -actin cDNA from the diluted RT reactions, usually between
  • RNA fingerprinting by PCR, primed with oligonucleotides of arbitrary sequence was performed on RNAs isolated from peripheral human blood. Bands which appeared to be differentially expressed were cloned.
  • RNA total cell RNA was isolated from buffy coat cells as described above.
  • cDNA was made from one to five ⁇ g of each isolated RNA. All cDNAs were normalized for similar amounts of ⁇ -actin cDNA by RT-PCR. RT-PCR products were electrophoresed through agarose.
  • UCBP Band #35 SEQ ID NO:l
  • UCBP Band #35 matches an EST derived from a fetal brain cDNA library (GenBank Accession #T03013). Down regulation of this band in the peripheral blood of metastatic prostate cancer patients was confirmed by relative quantitative RT-PCR.
  • RNA fingerprinting was used to identify differentially expressed RNA species according to the pairwise sequential method of McClelland et al. (1994), as modified to use larger (17-25 mer) arbitrary oligonucleotides.
  • PCR amplification products were labeled using ⁇ -32P-dCTP and were visualized by autoradiography after electrophoresis on denaturing polyacrylamide gels. A number of bands appeared to be differentially expressed, and were cloned as described above.
  • UC Band #321 was confirmed by RT-PCR to be down regulated in the peripheral blood of prostate cancer patients, with a four-fold decrease observed compared with normal individuals.
  • UC Band #302 and UC Band #325 were both observed to be up regulated in the peripheral blood of metastatic prostate cancer patients.
  • UC Band #302 is identical in sequence to a portion of the sequence of elongation factor 1- ⁇ (GenBank Accession #X03558). This band was modestly increased between 1.6 and 2-fold in metastatic cancer patients compared with normal individuals.
  • UC Band #325 was found to consist of two different alternatively spliced forms of mRNA, encoded by the interleukin-8 (IL-8) gene.
  • UC Band #325-1 the previously identified mRNA species of IL-8 (Genbank Accession #Y00787), is approximately seven- fold more abundant in the peripheral blood of metastatic prostate cancer patients.
  • the alternatively spliced IL-8 mRNA, containing intron #3 of the IL-8 gene (Genbank Accession #M28130) is up to seven-fold less abundant in the peripheral blood of metastatic prostate cancer patients.
  • IA shows relative quantitative RT-PCR of the differential expression of IL-8 (-UC235) in peripheral blood of patients with metastatic prostate cancer (M) and normal individuals (N) at different PCR cycles (cy).
  • the two alternatively spliced forms of the IL-8 mRNA are observed.
  • the upper band (int.+) includes intron 3 in the mature mRNA.
  • the lower band (int.-) lacks intron 3.
  • Fig. IB shows relative quantitative RT-PCR showing Differential Expression of IL-8 (UC325) in peripheral blood of patients with metastatic prostate cancer in lanes 1-5 and a pool of normal individuals (N).
  • the alternatively spliced forms of the IL-8 mRNA observed are different between normal individuals and those with prostate cancer.
  • RNAs and proteins genes and gene products for the above described markers of metastatic prostate cancer are included within the scope of the disclosure herein described. It will also be recognized that the diagnosis and prognosis of metastatic prostatic cancer by detection of the nucleic acid products of these genes are included within the scope of the present invention. Serological and other assays to detect these mRNA species or their translation products are also indicated. It is obvious that these assays are of utility in diagnosing metastatic cancers derived from prostate and other tissues.
  • RNA finge ⁇ rinting to identify mRNA species that are differentially expressed in the peripheral blood of patients with asymptomatic diseases or in patients with symptoms that are insufficient for a definitive diagnosis. It will be appreciated that this technique is applicable not only to the detection and diagnosis of prostate and other cancers, but also to any other disease states which produce significant effects on lymphocyte gene expression. Uses which are contemplated within the scope of the present disclosure include the detection and diagnosis of clinically significant diseases that requires medical intervention, including but not limited to asthma, lupus erythromatosis, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, autoimmune thyroiditis, ALS, interstitial cystitis and prostatitis.
  • Oligonucleotides used to examine the expression of genes UCPB Band #35 (previously uncharacterized gene).
  • the DNA sequences of the markers of metastatic prostate cancer were determined by Sanger dideoxy sequencing as detailed above. The identified sequences are provided in Table 4.
  • UCPB Band #35 (SEQ ID NO:l) Matches a fetal brain EST, GenBank Accession # T03013
  • a total of 164 serum specimens from normal men or men with a biopsy confirmed diagnosis of BPH or prostate cancer were studied. These serum specimens were provided by Dr. George Wright from the Virginia Prostate Center at the Eastern Virginia Medical School and by Dr. Robert Vessella from the University of Washington or were normal donors from UroCor,
  • Table 5 shows the distribution of the total PSA levels, the f/t PSA ratios, and the UC325 levels for the 164 patients, broken down by normals, BPH, and Stages A, B, C, & D prostate cancer. Only the BPH, Stage A, Stage B, and Stage C prostate cancer patients were included in the statistical analysis.
  • Table 6 illustrates the ability for f/t PSA ratio at three different cutoffs to differentiate prostate cancer and BPH in the inventors' patient sample.
  • UC325 (IL-8) and t-PSA are analyzed at single Classification and Regression Tree (CART) cutoff points for the same outcome. Note the significant improvement in both sensitivity and specificity contributed by the UC325 (IL-8) serum assay to detect clinically organ confined.
  • the combination of UC325 (IL-8), treated as a continuous variable, and t-PSA or f/t PSA ratio provides a highly predictive multivariate test system to diagnose CaP (clinical stages A & B) without any interference provided by BPH in the inventors' patient subset.
  • FIG. 4 shows the ability of UC325 (IL-8) alone to distinguish BPH and Stages A, B, and C prostate cancer.
  • Figure 5 shows the ability of the combination of UC325 (IL-8) and total PSA (t-PSA) to distinguish BPH and Stages A, B and C prostate cancer.
  • Figure 6 shows the ability of the combination of UC325
  • Table 8 clearly demonstrates a relationship between tumor burden and serum UC-325 gene product measured by IL-8 assay. Note that as biopsy-confirmed clinical stage of the cancer increases, so does the IL-8 serum marker concentration, whereas the same relationship did not occur with [t-PSA] or f/t PSA ratio.
  • RNA fingerprinting by PCR primed with oligonucleotides of arbitrary sequence.
  • RNA fingerprinting displays PCRTM amplified cDNA fragments that represent a sample of RNA species derived from a population of total cell RNAs.
  • comparisons of similarly produced finge ⁇ rints representing RNA populations from cells of differing physiologic states identifies mRNA species whose relative abundances vary between the examined physiologic states.
  • RNA finge ⁇ rinting identified two cDNA fragments derived from mRNA species that had higher steady state abundances in the peripheral blood leukocytes of patients with recurrent metastatic prostate cancer as compared to a group of healthy volunteers.
  • RNA finge ⁇ rinting and relative quantitative RT-PCRTM Contaminating genomic DNA was removed from the total RNAs by digestion with RNase free DNasel (GIBCO-BRL, Gaithersburg, MD).
  • RNase free DNasel GRBCO-BRL, Gaithersburg, MD.
  • PCRTM based applications of RNA finge ⁇ rinting and relative quantitative RT-PCRTM it is absolutely critical that the total RNA is completely free of genomic DNA. Typically, 5.0 to 10.0 ⁇ g of total RNA was digested with RNase free DNasel (GIBCO-BRL, Gaithersburg, MD).
  • 500 ng to 1.0 ⁇ g of each DNasel treated RNA was resuspended in water. These were used as templates for PCRTM using oligonucleotide primers that anneal to exons 3 and 4 of the gene encoding PSA (exon 3: 5' GCCTCAGGCTGGGGCAGCATT 3' SEQ ID NO:22, exon 4: 5' GGTCACCTTCTGAGGGTGAACTTGC 3' SEQ ID NO:23).
  • RNA finge ⁇ rinting and relative quantitative RT-PCRTM 500 ng to 1.0 ⁇ g of RNA was electrophoresed on a 1.2% agarose Tris Acetate EDTA (TAE) to visualize the ribosomal RNAs (Fridell et al, 1995). Only RNA preparations for which the 28S ribosomal RNA could be visualized were selected for further analysis by RNA finge ⁇ rinting and relative quantitative RT-PCRTM.
  • RNA finge ⁇ rinting with arbitrarily chosen oligonucleotide primers is conceptually similar to differential display (Liang and Pardee, 1992), except that oligonucleotides of arbitrary sequence are used to prime both strands of cDNA synthesis instead of just second strand synthesis, as in differential display.
  • the strategy of RNA finge ⁇ rinting used was similar to that described in Ralph et al. (1993) except that oligonucleotide primers used were composed of two discrete domains.
  • the 5' domain of these oligonucleotides consisted of ten nucleotides that complemented sequences from either the T7 promotor or the Ml 3 reverse sequencing primer.
  • the 3' domains of these oligonucleotides were 8-mer sequences predicted to anneal frequently to the protein-coding regions of mRNAs in a permiscuous fashion (Lopez-Nieto and Nigam, 1996). These oligonucleotides were then used in a sequential pairwise strategy that optimizes the amount of mRNA complexity that can be surveyed with limited numbers of primers and starting RNA.
  • RNA pools were finge ⁇ rinted. These two pools were each created by combining equal amounts of peripheral blood total RNA from five individuals. One pool was constructed by pooling RNA from five healthy individuals while the other pool was derived from five individuals with recurring metastatic prostate cancer.
  • RNA was digested with RNase H and heat inactivated at 70°C as directed by the supplier.
  • One-tenth (4.0 ⁇ l) of the first strand cDNA reaction mixture was used in the fingerprinting PCRTM reaction. As many as ten different RNA finge ⁇ rints were generated from each first strand cDNA reaction.
  • PCRTM mix solution was added to the first strand cDNA.
  • PCRTM finge ⁇ rinting was performed with one cycle of 94°C for 2:00 min, 48°C for 5:00 min then 72°C for 5:00 min.
  • PCRTM products were visualized by autoradiography.
  • UC331 was identified in a study in which the first permiscuous primer used in the reverse transcription reaction had the sequence 5' ACGACTCACTATAAGCAGGA 3' (SEQ ID NO:24).
  • the second permiscuous primer that was used in the PCRTM finge ⁇ rinting reaction that identified UC331 was 5' AACAGCTATGACCATCGTGG 3' (SEQ ID NO:25).
  • UC332 was identified in a study in which the first permiscuous primer used in the reverse transcription reaction had the sequence
  • UC331 and UC332 were compared to those deposited in release 101 of GenBank (July 1997) using the LasergeneTM software package (DNAstar, Inc., Madison, WI).
  • the DNA sequence of these cDNA fragments when compared to the GenBank database, revealed that the mRNAs, from which these cDNA fragments were derived, were previously uncharacterized.
  • UC331 nor UC332 are genes whose products have been previously characterized as being significant in any physiological pathway, both UC331 and UC332 match sequences on the GenBank data base. In the case of UC331, these matches are confined to ESTs.
  • UC331 was identical within the limits of sequencing accuracy to several human EST sequences.
  • the human EST sequences with high similarity to UC331 could be assembled into a virtual contig that predicts the sequence of a larger mRNA.
  • the ends of the UC331 contig were then used to requery the EST data base whereby more ESTs were identified that extended the contig. This process was continued until the UC331 contig predicted a mRNA with an ORF and a poly-A tail.
  • a description of the human ESTs that were used to construct the UC331 contig are provided in Table 9.
  • the sequence of the UC331 contig and the ORF was identified at its 5' end. A significant feature of this contig is that the ORF extends all the way to its 5' end. This indicates that the UC331 mRNA extends further 5' than is indicated by the contig constructed from the EST database. TABLE 9
  • mouse EST sequences were identified with significant similarity. This was especially true in the region spanning the putative ORF. The identified mouse ESTs were found to have areas of overlap and similarity with each other that permitted them to be assembled into a mouse UC331 virtual contig in a process that was identical to that used to create the human contig. The mouse UC331 virtual contig was also observed to have an ORF at its 5' end and a poly-A tail at its 3' end. A description of the mouse ESTs that were used to construct this contig are provided in Table 10.
  • the ORFs of the mouse and human UC331 contigs were conceptually translated and the amino acid sequences were compared.
  • the amino acid sequence of the human UC331 ORF was used to query the Swiss, PIR and Translation release 101 using the LasergeneTM software package.
  • the mouse and human sequences are collinear and identical at 151 positions (96%) with five of the six differences being conservative substitutions.
  • This putative protein domain is highly acidic with 26 acidic and 17 basic amino acids. There were also 48 hydrophobic and 41 polar amino acids predicted.
  • no significant matches were found to any previously characterized vertebrate proteins.
  • ZK353.1 PIR Accession number S44654
  • the mammalian amino acid sequence is similar and collinear with the C-terminal 157 amino acids of the putative C. elegans protein.
  • the C-terminal 157 amino acid sequence of the ZK353.1 is also highly acidic with 31 acidic and only 20 basic amino acids. Over the 203 amino acids for which a comparison can be made the ZK353.1 amino acid sequence is identical to the human or mouse sequence at 84 (41%) positions with many of the differences representing conservative substitutions.
  • the putative C. elegans protein, ZK353.1 has no currently known function. Its existence is predicted from the C. elegans genome sequencing effort (Sulston et al, 1992).
  • the polypeptide sequence for ZK353.1 is a conceptual translation of an area on the C. elegans chromosome III (GB accession number CELZK353).
  • the predicted sequence for ZK353.1 is 548 amino acids long and includes an additional 371 amino acids that are N-terminal of the domain with similarity to the predicted amino acid sequence of UC331. If UC331 is the mammalian homolog of ZK353.1 and if UC331 is collinear with the C.
  • oligonucleotides were designed to direct the PCRTM amplification of large cDNA fragments predicted to be continuous from the virtual contig but which contain significantly more sequence than can be found in any single EST.
  • UC332 did not match any EST sequences but was identical to a portion of a previously sequenced full length cDNA with a GenBank accession number of D87451.
  • RNAs identified by RNA finge ⁇ rinting or differential display as being differentially regulated turn out not to be so when examined by independent means. It is, therefore, critical that the differential expression of all mRNAs identified by RNA finge ⁇ rinting be confirmed as such by an independent methodology.
  • two different formats for a relative quantitative RT-PCRTM were performed. The first format of this assay examined normalized pools of cDNA constructed by combining equal amounts of cDNA from various individuals representing similar physiologic states.
  • a cDNA pool representing 8 healthy volunteers was compared to a pool representing 10 individuals with recurrent metastatic prostate cancer.
  • a third pool representing 10 individuals with recurrent metastatic breast cancer was also examined.
  • the inclusion of the breast cancer patient samples in this study was made to determine if the mRNAs examined were being differentially regulated in the immune system in a response that was specific for prostate cancer or if the response was more general to metastatic cancer in general.
  • triplicate PCRTM was performed. Each of the three replicates were terminated at a different cycle number of PCRTM. This format of relative quantitative RT-PCRTM insures that the results taken for relative quantitation represent the PCRsTM when they are in the log linear portions of their amplification curves where such quantitation is most accurate.
  • RNA-free total RNA from the peripheral blood of healthy volunteers or patients with either metastatic prostate or breast cancer were converted into first strand cDNA using the SuperscriptTM Preamplification System for First Strand cDNA Synthesis (GIBCO-BRL, Cat# 18089-011) following the directions provided by the supplier.
  • These cDNAs were then normalized to contain equal concentrations of amplifiable cDNA by PCRTM amplification of ⁇ -actin cDNA using the primers 5' GGAGCTGCCTGACGGCCAGGTCATC 3' (SEQ ID NO:28) and 5' GAAGCATTTGCGGTGGACGATGGAG 3' (SEQ ID NO:9).
  • a typical PCRTM program would be 94°C for 1 :15 min, followed by 22 cycles of 94°C for 45 sec, 55°C for 45 sec and 72°C for 1 :15 min. This was followed by final extension of 72°C for 5:00 min.
  • PCRTM products were visualized by gel electrophoresis through 1.5% agarose TAE gels stained with ethidium bromide. Images of the gels were captured, digitized and analyzed using the IS-1000 Digital Imaging System (Alpha Innotech Co ⁇ .). The concentrations of the cDNAs were adjusted by adding various amounts of water to create cDNA stocks that contained equal concentrations of amplifiable ⁇ -actin cDNA.
  • the cDNA derived from the reverse transcription of 5.0 ⁇ g of RNA resulted in enough normalized cDNA to perform 50-200 RT-PCRTM reactions.
  • Equal amounts of the normalized cDNA stock from individuals having the same disease state were pooled. Pools of cDNAs from healthy volunteers, patients with metastatic prostate cancer and metastatic breast cancer were produced. These pools were then examined by PCRTM for ⁇ -actin to determine that they contained equal amounts of amplifiable cDNA.
  • PCRTM PCRTM was terminated at differing cycle numbers (cycle 22, cycle 24, and cycle 26), and the products were visualized by electrophoreses and ethidiumn bromide staining. Images were captured and quantitated using a digital image analysis system. At all three cycle numbers examined, there are relatively similar band intensities representing the three cDNA pools and increasing band intensity with increasing cycle number, verifying that the observations are being made in the log linear range of the amplification curves. Similar band intensities indicate similar relative concentrations of ⁇ -actin mRNA in the RNAs from individuals from which these cDNA pools were constructed.
  • UC331 The oligonucleotides used in the relative quantitative RT-PCRTM studies that independently confirmed the differential expression of UC331 were designed from the sequence in the human UC331 virtual contig. These UC331 specific oligonucleotides had the sequences of 5' CTGGCCTACGGAAGATACGACAC 3' (SEQ ID NO:31) and 5'
  • ACAATCCGGAGGCATCAGAAACT 3' (SEQ ID NO:32). These oligonucleotides direct the amplification of a 277 nucleotide long PCRTM product that is specific for UC331.
  • the oligonucleotides used in the relative quantitative RT-PCRTM studies that independently confirmed the differential expression of UC332 were designed using the sequences of the cDNA with the GenBank accession number D87451.
  • These UC332 specific oligonucleotides had the sequences 5' AGCCCCGGCCTCCTCGTCCTC 3' (SEQ ID NO:33) and 5' GGCGGCGGCAGCGGTTCTC 3' (SEQ ID NO:34).
  • These oligonucleotides direct the amplification of a 140 nucleotide long PCRTM product that is specific for UC332.
  • the second format of relative quantitative RT-PCRTM used to examine the differential expression of UC331 examined the relative abundance of UC331 mRNA in the peripheral blood of healthy individuals or individuals with recurrent metastatic cancer.
  • the individuals examined in this study were the same as those whose cDNAs were combined to construct the pools examined as described above.
  • PCRTM cycle numbers relative quantitative RT-PCRTM would be most informative, these individuals were examined for the relative abundance of ⁇ -actin and UC331 mRNAs present in their peripheral blood leukocytes.
  • PCRTM was for 22 cycles. All individuals examined contain roughly equal amounts of amplifiable ⁇ -actin cDNA.
  • Relative quantitative RT-PCRTM of UC331 cDNA was conducted using reverse transcribed from RNA isolated from the peripheral blood of eight healthy volunteers (group N), ten individuals with recurrent methstatic prostate cancer (group P), or ten individuals with recurrent metastatic breast cancer (group B). PCRTM was for 30 cycles. As was seen in the study using the pooled cDNAs, the results of the relative quantitative RT-PCRTM for UC331 using cDNA from individuals contrasts sha ⁇ ly with that observed for ⁇ -actin.
  • the intensity of the band representing the abundance of the UC331 mRNA in peripheral blood leukocytes was greater for all of the patients with either metastatic prostate or breast cancer as compared to the intensity of the UC331 band representing the mRNA level in the peripheral blood leukocytes of healthy volunteers. Therefore, the elevated UC331 mRNA levels indicated by the relative quantitative RT-PCRTM results using the pooled cDNA templates was caused by an elevated mRNA level in all individuals comprising the pools and not from a subset of individuals with very high elevations in UC331 mRNA levels. This study is a second independent confirmation of the differential expression of the UC331 mRNA.
  • UC331 As is indicated by the wide distribution of tissues from which the ESTs used to assemble the UC331 contigs (Table 9), UC331 is widely expressed in many tissue and cell types. However, because most of ESTs comprising UC331 are from normalized libraries, little information can be gained from this data on the relative abundance of the UC331 mRNA in different tissues. Also, while the extension of the ORFs of the mouse and human UC331 contigs all the way to their 5' ends and the similarity of mammalian UC331 mRNAs to a much larger putative C. elegans mRNA both predict that the mammalian UC331 mRNA extends even further 5', the exact size of the UC331 mRNA was unknown.
  • a Northern blot of poly-A plus RNA from eight different human tissues was probed with the 850 nucleotide long RT-PCRTM product described above labeled with P.
  • Approximately 2.0 ⁇ g of poly-A plus RNA from spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes were loaded in each lane.
  • UC331 mRNA is expressed in all eight human tissue and cell types. Size standards indicate a message size of approximately 1.75 kb.
  • UC331 is least abundant in peripheral blood leukocytes but is highly expressed in the thymus, demonstrating a difference in expression between cells of different developmental stages in the immune system. UC331 is most abundantly expressed in the testes.
  • the UC331 mRNA is about 1.75 kb which indicated that the mRNA only extends about 350 nucleotides further 5' than is accounted for by the virtual contig shown in SEQ ID NO:29.
  • the translation product of the virtual contig is shown in SEQ ID NO:30.
  • the putative C. elegans mRNA extends much more 5' than do the mammalian mRNA species.
  • UC332 was analyzed in much the same way as UC331 was.
  • GenBank When the sequence of the cDNA fragment from the RNA finge ⁇ rinting gel representing UC332 was used to query GenBank, no ESTs were identified.
  • the sequence of the UC332 cDNA fragment did, however, identify a sequence of a full length cDNA, KA000262 (GB accession number D87451).
  • KA000262 (hereafter referred to interchangeably with the name, UC332) was determined as part of a project to examine previously unidentified mRNAs expressed in the bone marrow myeloblast cell line, KG-1 (Nagase et al, 1996).
  • This mRNA contains an ORF encoding a putative protein with 761 amino acid sequence.
  • Perhaps the most striking feature of this polypeptide sequence is the appearance of a C3HC4 RING zinc finger or RING finger motif (Freemont, 1993) located between amino acids 175 and 216.
  • the RING finger domain binds two zinc ions in a conserved structure that has been resolved (Barlow et al, 1994).
  • RING finger domains have been identified in dozens of proteins derived from eukaryotes as diverse as yeasts, flies, birds, nematodes and humans. In most of these cases, the RING finger containing proteins have been shown to be essential for some important biological process although the these processes vary considerably one from another. Among these mammalian encoded RING finger proteins are several genes implicated in the ontogeny of cancer including the ret viral oncogene (Takahashi et al, 1988) and bmi-1, a gene whose product collaborates with myc induced transformation (Haupt et al, 1991).
  • the BRCA-1 tumor suppressor gene involved in hereditary breast and ovarian cancer susceptibility contains a RING finger domain (Miki et al, 1994), and MAT-1, a novel 36 kDa RING finger protein, is required for the assembly of enzymatically active CDK7- cyclin H complexes (Tassan et al, 1995).
  • NLS nuclear localization signals
  • the first NLS domain would have 8 of eleven positions as basic amino acids while the second motif would have 5 of 6 amino acids being basic.
  • the second NLS motif in UC332 is located near the C-terminal end between positions 739 and 750 in the amino acid sequence. This domain has 8 of 12 amino acids as basic residues with a core of 5 consecutive lysines and arginines. The presence of these putative NLS in the amino acid sequence of UC332 suggest the possibility that
  • UC332 plays an important role in regulating the expression of other genes. Finally, the amino acid sequence of UC332 lacks a signal sequence for cellular export or an obvious hydrophobic transmembrane domains.
  • PCRTM was for 26 cycles. The results of this study are similar to those obtained when the pooled cDNAs were used as PCRTM templates. All of the cancer patients had higher levels of UC332 mRNA in their peripheral blood leukocytes than did any of the healthy volunteers.
  • UC332 encoding a RING finger protein
  • RING finger proteins have been shown to participate in the regulation of several important lymphocytic processes (Patarca et al, 1988; Fridell et al, 1995; Takeuchi et al, 1996; van Arsdale et al, 1997; Nakano et al, 1996).
  • the observed differential regulation of the RING protein encoding mRNA, UC332, in the immune response of patients with metastatic breast or prostate cancer strongly suggests that UC332 participates in regulating .this immune response.
  • compositions and methods disclosed and claimed herein may be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred embodiments, it is apparent that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention.
  • UC325-1 is derived from the IL-8 gene (Genebank Accession #M28130).
  • UC325-1 and UC325-2 an alternatively spliced form that includes the third intron of the IL-8 primary transcript, are transcribed from the IL-8 gene.
  • Our definition of IL-8 gene products means all mRNAs transcribed from the IL-8 gene, the polypeptides encoded by those mRNAs and their post- translationally processed protein products.
  • Patarca Scwartz, Singh, Kong, Mu ⁇ hy, Anderson, Sheng, Singh, Johnson, Guarnagia, Durfee, Blattner, Cantor, " ⁇ t-1, an intracellular protein from helper/inducer T cells that regulates gene expression of interleukin 2 receptor and human immunodeficiency virus type 1," Proc. Natl. Acad. Sci. USA, 85:2733-2737, 1988.
  • C-RZF RING zinc finger gene
  • AATTCATAAA AAAATTCATT CTCTGTGGTA TCCAAGAATC AGTGAAGATG CCAGTGAAAC 540

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention, qui a trait à des méthodes diagnostiques permettant de déceler des états pathologiques chez l'homme, décrit également les sondes génétiques et les techniques afférentes utilisées pour déceler des états pathologiques et surveiller leur évolution. Elle concerne, plus particulièrement, des sondes et des techniques permettant d'évaluer la présence d'espèces d'ARN dont l'expression dans le sang périphérique de personnes souffrant desdits états pathologiques diffère de celle ayant lieu chez des individus en bonne santé. L'invention porte, en outre, sur un modèle de diagnostic à plusieurs variables s'appliquant au cancer de la cancer de la prostate chez des sujets dont le taux plasmatique total d'antigène prostatique spécifique (PSA) est modérément élevé (≥ 2,0 ng/ml). Les résultats de dosages sériques concernant le produit génique UC325 [Interleukine-8(IL-8)], le taux plasmatique total d'antigène prostatique spécifique (t-PSA) ainsi que les rapports relatifs à l'absence de PSA/PSA total (f/t PSA) ont été combinés pour renforcer la sensibilité du diagnostic du cancer de la prostate dans une population relevant de l'urologie diagnostiquée comme étant atteinte, soit d'un cancer de la prostate limité à l'organe proprement dit (stade clinique A et B), soit d'un cancer de la prostate non limité à l'organe (stade clinique C ou D) ou encore d'une hyperplasie prostatique bénigne (BPH). L'invention traite également des possibilités supplémentaires qu'offre la connaissance des taux sériques en produit génique UC325 de définir avec exactitude les stades d'évolution du cancer de la prostate, indépendamment des taux de PSA, qu'il s'agisse de t-PSA ou de f/t PSA.
EP97951529A 1996-12-06 1997-12-05 DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER Ceased EP0960214A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3261996P 1996-12-06 1996-12-06
US32619P 1996-12-06
US3270196P 1996-12-12 1996-12-12
US32701P 1996-12-12
US4157697P 1997-03-24 1997-03-24
US41576P 1997-03-24
PCT/US1997/022105 WO1998024935A1 (fr) 1996-12-06 1997-12-05 DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER

Publications (2)

Publication Number Publication Date
EP0960214A1 true EP0960214A1 (fr) 1999-12-01
EP0960214A4 EP0960214A4 (fr) 2004-08-04

Family

ID=27364173

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97951529A Ceased EP0960214A4 (fr) 1996-12-06 1997-12-05 DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER

Country Status (4)

Country Link
EP (1) EP0960214A4 (fr)
AU (1) AU722819B2 (fr)
CA (1) CA2273847C (fr)
WO (1) WO1998024935A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO972006D0 (no) * 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
WO2000040749A2 (fr) * 1999-01-06 2000-07-13 Genenews Inc. Technique de detection de transcrits geniques dans le sang et leur utilisation
FI990382A0 (fi) * 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
ATE364721T1 (de) * 1999-06-28 2007-07-15 Source Precision Medicine Inc Verfahren zum charakterisieren von biologischen bedingungen, die kalibrierte genexpressionsprofile verwenden
KR20020064298A (ko) * 1999-10-13 2002-08-07 시쿼넘, 인코포레이티드 다형성 유전 마커를 동정하기 위한 데이타베이스 및 이의제조 방법
AU2002241720A1 (en) * 2000-11-08 2002-06-18 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
EP1425412A2 (fr) * 2000-11-28 2004-06-09 University Of Cincinnati Evaluation sanguine de maux
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1427858A2 (fr) 2001-09-12 2004-06-16 F. Hoffmann-La Roche Ag Marqueurs specifiques a la sclerose en plaques
KR20040064275A (ko) 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인
GB0200595D0 (en) * 2002-01-11 2002-02-27 Oxford Glycosciences Uk Ltd Quantitation of differential expression
CA2498418A1 (fr) * 2002-09-10 2004-03-25 Guennadi V. Glinskii Methodes de segregation de genes et de classification d'echantillons biologiques
MXPA05006804A (es) * 2002-12-19 2006-03-30 Source Precision Medicine Inc Identificacion, monitoreo y tratamiento de enfermedad infecciosa y caracterizacion de condiciones inflamatorias relacionadas con enfermedad infecciosa usando perfiles de expresion genica.
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
CN101039951A (zh) * 2003-11-03 2007-09-19 基因信息公司 肝癌生物标志物
EP1727911B1 (fr) 2004-03-26 2013-01-23 Sequenom, Inc. Clivage specifique de base de produits d'amplification specifique a la methylation en combinaison avec une analyse de masse
GB0510352D0 (en) * 2005-05-20 2005-06-29 Optomed As Methods of prostate cancer diagnosis and prostrate tumour analysis
AU2006259306B2 (en) 2005-06-16 2012-02-16 Life Technologies Corporation Gene expression profiling for identification and monitoring of multiple sclerosis
EP1916301A4 (fr) * 2005-08-11 2009-04-01 Banyu Pharma Co Ltd Proceded evaluation d un compose a l aide d une molecule sur le trajet rb comme indice et procedede diagnostic moleculaire
AU2006294477A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
WO2010006048A2 (fr) 2008-07-08 2010-01-14 Source Precision Medicine, Inc. Profilage de l'expression génique pour la prédiction de la survie de sujets atteints d'un cancer de la prostate
CA2748823A1 (fr) 2009-01-06 2010-07-15 Source Precision Medicine, Inc. D/B/A Source Mdx Profilage d'expression genique pour l'identification, la surveillance et le traitement du cancer de la prostate
EP2407555A1 (fr) 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Procédés et kits pour le diagnostic du cancer de la prostate
EP2407554A1 (fr) 2010-07-14 2012-01-18 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Procédés et kits pour le diagnostic du cancer de la prostate

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010343A1 (fr) * 1992-10-29 1994-05-11 Thomas Jefferson University Procedes de detection de micrometastase du cancer de la prostate
WO1996017080A1 (fr) * 1994-11-26 1996-06-06 Imperial Cancer Research Technology Limited Detection de tumeurs
WO1996021671A1 (fr) * 1995-01-11 1996-07-18 The Trustees Of Columbia University In The City Of New York Developpement de sondes d'adn et de reactifs immunologiques specifiques de molecules exprimees sur une surface cellulaire et genes associes a la transformation
US5543296A (en) * 1991-06-26 1996-08-06 Hoffman-La Roche Inc. Detection of carcinoma metastases by nucleic acid amplification
WO1998010098A1 (fr) * 1996-09-06 1998-03-12 The Trustees Of Columbia University In The City Of New York Utilisation d'un gene induisant une tumeur prostatique pour detecter des cellules cancereuses
WO1999015658A2 (fr) * 1997-09-23 1999-04-01 Incyte Pharmaceuticals, Inc. Molecules regulatrices humaines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2250993B (en) * 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
US5459037A (en) * 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5677125A (en) * 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543296A (en) * 1991-06-26 1996-08-06 Hoffman-La Roche Inc. Detection of carcinoma metastases by nucleic acid amplification
WO1994010343A1 (fr) * 1992-10-29 1994-05-11 Thomas Jefferson University Procedes de detection de micrometastase du cancer de la prostate
WO1996017080A1 (fr) * 1994-11-26 1996-06-06 Imperial Cancer Research Technology Limited Detection de tumeurs
WO1996021671A1 (fr) * 1995-01-11 1996-07-18 The Trustees Of Columbia University In The City Of New York Developpement de sondes d'adn et de reactifs immunologiques specifiques de molecules exprimees sur une surface cellulaire et genes associes a la transformation
WO1998010098A1 (fr) * 1996-09-06 1998-03-12 The Trustees Of Columbia University In The City Of New York Utilisation d'un gene induisant une tumeur prostatique pour detecter des cellules cancereuses
WO1999015658A2 (fr) * 1997-09-23 1999-04-01 Incyte Pharmaceuticals, Inc. Molecules regulatrices humaines

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ANDRAWIS RAMEZ I ET AL: "Expression of interleukin-8 in prostate cancer, benign prostatic hyperplasia, and bladder cancer" JOURNAL OF UROLOGY, vol. 155, no. 5 SUPPL., 1996, page 512A XP009031019 Ninety-first Annual Meeting of the American Urology Association;Orlando, Florida, USA; May 4-9, 1996 ISSN: 0022-5347 *
BERGHELLA ANNA MARIA ET AL: "Prognostic significance of immunological evaluation in colorectal cancer" CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 11, no. 6, 1996, pages 355-361, XP009030771 ISSN: 1084-9785 *
BREW R ET AL: "Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells" EUROPEAN JOURNAL OF CANCER, vol. 32A, no. 12, 1996, pages 2142-2147, XP002281051 ISSN: 0959-8049 *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; NLM1696063 April 1990 (1990-04), "Clinical Study of tumour markers in prostatic cancer" Database accession no. NLM1696063 *
DI CELLE P F ET AL: "Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein." BLOOD. UNITED STATES 1 JUL 1994, vol. 84, no. 1, 1 July 1994 (1994-07-01), pages 220-228, XP002268404 ISSN: 0006-4971 *
EDMONDS B T ET AL: "Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma" JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 109, no. part 11, November 1996 (1996-11), pages 2705-2714, XP002257189 ISSN: 0021-9533 *
FERRER FERNANDO A ET AL: "Cytokine regulation of angiogenesis factors in human prostate cancer" JOURNAL OF UROLOGY, vol. 155, no. 5 SUPPL., 1996, page 351A XP009031018 Ninety-first Annual Meeting of the American Urology Association;Orlando, Florida, USA; May 4-9, 1996 ISSN: 0022-5347 *
GREENE GRAHAM F ET AL: "Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique" AMERICAN JOURNAL OF PATHOLOGY, vol. 150, no. 5, 1997, pages 1571-1582, XP009031223 ISSN: 0002-9440 *
GUTMAN MORDECHAI ET AL: "Regulation of interleukin-8 expression in human melanoma cells by the organ environment" CANCER RESEARCH, vol. 55, no. 11, 1995, pages 2470-2475, XP001181350 ISSN: 0008-5472 *
HELLER R A ET AL: "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, no. 94, pages 2150-2155, XP002076789 ISSN: 0027-8424 *
ISAACS J T: "MOLECULAR MARKERS FOR PROSTATE CANCER METASTASIS DEVELOPING DIAGNOSTIC METHODS FOR PREDICTING THE AGGRESSIVENESS OF PROSTATE CANCER" AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 150, no. 5, May 1997 (1997-05), pages 1511-1521, XP000997986 ISSN: 0002-9440 *
LAMERZ R. ET AL: "Serum Marker Combinations of Human Breast Cancer (Review)" IN VIVO, vol. 7, no. 6B, 1993, pages 607-614, XP009075408 Athens *
NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES, VI. THE CODING SEQUENCES OF 80 NEW GENES (KIAA0201-KIAA0280) DEDUCED BY ANALYSIS OF CDNA CLONES FROM CELL LINE KG-1 AND BRAIN" DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 3, no. 5, 1996, pages 321-329, XP000891809 ISSN: 1340-2838 *
PENCIL S D ET AL: "Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma." BREAST CANCER RESEARCH AND TREATMENT. NETHERLANDS 1993, vol. 25, no. 2, 1993, pages 165-174, XP009031206 ISSN: 0167-6806 *
RASSEKH C.J. ET AL: "Circulating Markers in Squamous Cell Carcinoma of the Head and the Neck: A Review" ORAL ONCOL. EUR. J. CANCER, vol. 30B, no. 1, 1994, pages 23-28, *
See also references of WO9824935A1 *
UEDA TAKASHI ET AL: "Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis" JOURNAL OF GASTROENTEROLOGY, vol. 29, no. 4, 1994, pages 423-429, XP009030767 *
WELLSTEIN A ET AL: "Growth factors as targets in tumor therapy" INTERNATIONAL JOURNAL OF PHARMACOGNOSY, vol. 33, no. SUPPL., 1995, pages 35-47, XP009030768 ISSN: 0925-1618 *
ZHANG J ET AL: "Rapid identification of differentially expressed RNA transcripts in apoptotic T lymphocytes." JOURNAL OF IMMUNOLOGICAL METHODS. NETHERLANDS 9 SEP 1996, vol. 195, no. 1-2, 9 September 1996 (1996-09-09), pages 113-123, XP004021260 ISSN: 0022-1759 *

Also Published As

Publication number Publication date
WO1998024935A1 (fr) 1998-06-11
AU5515198A (en) 1998-06-29
AU722819B2 (en) 2000-08-10
CA2273847C (fr) 2013-08-13
EP0960214A4 (fr) 2004-08-04
CA2273847A1 (fr) 1998-06-11

Similar Documents

Publication Publication Date Title
AU722819B2 (en) Diagnosis of disease state using mRNA profiles
US6190857B1 (en) Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US6090559A (en) Biomarkers for the detection of prostate cancer
CA2744096C (fr) Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
US6218529B1 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP2444505B1 (fr) Marqueurs urinaires permettant de detecter un cancer de la vessie
US20030219760A1 (en) Diagnostic and prognostic tests
US7807785B2 (en) Androgen regulated prostate specific nucleic acids
WO2003021229A2 (fr) Tests diagnostiques et pronostiques
KR102361679B1 (ko) Smpd1를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도
US7332270B1 (en) Diagnosis of disease state using mRNA profiles in peripheral leukocytes
Karavitaki et al. Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy
KR20200104106A (ko) 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커
AU712403B2 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate disease
KR102084658B1 (ko) 신장암 환자의 예후 진단 및 치료 전략 결정용 전이 특이적 마커
KR20210040921A (ko) 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12P 19/34 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040616

17Q First examination report despatched

Effective date: 20050309

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20070928